U.S. patent number 6,803,187 [Application Number 09/720,435] was granted by the patent office on 2004-10-12 for method for detection of drug-selected mutations in the hiv protease gene.
This patent grant is currently assigned to Innogenetics N.V.. Invention is credited to Lieven Stuyver.
United States Patent |
6,803,187 |
Stuyver |
October 12, 2004 |
**Please see images for:
( Certificate of Correction ) ** |
Method for detection of drug-selected mutations in the HIV protease
gene
Abstract
The present invention relates to a method for the rapid and
reliable detection of drug-selected mutations in the HIV protease
gene allowing the simultaneous charaterization of a range of codons
involved in drug resistance using specific sets of probes optimized
to function together in a reverse-hybridization assay. More
particularly, the present invention relates to a method for
determining the susceptibility to antiviral drugs of HIV viruses in
a biological sample, with said method comprising: a) if need be,
releasing, isolating or concentrating the polynucleic acids present
in the sample; b) if need be amplifying the relevant part of the
protease gene of HIV with at least one suitable primer pair; c)
hybrydizing the polynucleic acids of step a) or b) with at least
one of the following probes: probes specifically hybridizing to a
target sequence comprising codon 30; probes specifically
hybridizing to a target sequence comprising codon 46 and/or 48;
probes specifically hybridizing to a target sequence comprising
codon 50; probes specifically hybridizing to a target sequence
comprising codon 54; probes specifically hybridizing to a target
sequence comprising codon 82 and/or 84; probes specifically
hybridizing to a target sequence comprising codon 90; or the
complement of said probes; further characterized in that said
probes specifically hybridize to any of the target sequences
presented in FIG. (1), or the complement of said target sequences;
d) inferring from the result of step c) whether or not a mutation
giving rise to drug resistance is present in any of said target
sequences.
Inventors: |
Stuyver; Lieven (Herzele,
BE) |
Assignee: |
Innogenetics N.V. (Ghent,
BE)
|
Family
ID: |
8237061 |
Appl.
No.: |
09/720,435 |
Filed: |
June 25, 2001 |
PCT
Filed: |
June 22, 1999 |
PCT No.: |
PCT/EP99/04317 |
PCT
Pub. No.: |
WO99/67428 |
PCT
Pub. Date: |
December 29, 1999 |
Foreign Application Priority Data
|
|
|
|
|
Jun 24, 1998 [EP] |
|
|
98870143 |
|
Current U.S.
Class: |
435/5; 435/91.2;
536/24.3; 536/24.32 |
Current CPC
Class: |
C12Q
1/703 (20130101) |
Current International
Class: |
C12Q
1/70 (20060101); C12Q 001/20 () |
Field of
Search: |
;435/5,91.2
;536/24.3,24.32 |
Other References
Eastman 1998, J Virol. 72 (6) pp. 5154-5164..
|
Primary Examiner: Fredman; Jeffrey
Assistant Examiner: Switzer; Juliet C.
Attorney, Agent or Firm: Howrey Simon Arnold & White,
LLP
Parent Case Text
This application is a .sctn.371 national stage filing of
PCT/EP99/04317, filed 22 Jun. 1999 (published in English on 29 Dec.
1999 as WO 99/67428) and claiming priority to EP 98870143.9 filed
24 Jun. 1998.
Claims
What is claimed is:
1. Method for determining the susceptibility to antiviral drugs of
HIV viruses in a biological sample comprising polynucleic acids,
with said method comprising: a) releasing, isolating or
concentrating the polynucleic, acids present in the sample; b)
amplifying part of a protease gene of HIV comprising codons 82 and
84 from the polynucleic acids with at least one suitable primer
pair; c) hybridizing the polynucleic acids of step a) or b) with
probes having the sequence of SEQ ID NO:267 and SEQ ID NO:354, or
probes having sequence complementary to SEQ ID NO:267 and SEQ ID
NO:354; wherein said probes are immobilized on a solid support; and
d) inferring from the result of step c) whether or not a mutation
giving rise to drug resistance is present in said polynucleic
acids.
2. A method for determining the susceptibility to antiviral drugs
of HIV viruses in a biological sample comprising polynucleic acids,
with said method comprising: a) releasing, isolating or
concentrating the polynucleic acids present in the sample; b)
optionally, amplifying part of a protease gene of HIV comprising
codons 82 and 84 with at least one suitable primer pair; c)
hybridizing the nucleic acids of step a) or b) with probes having
the sequence of SEQ ID NO:267 and SEQ ID NO:354, or probes having
sequences complementary to SEQ ID NO:267 and SEQ ID NO:354; wherein
said probes are immobilized on a solid support; and d) inferring
from the result of step c) whether or not a mutation giving rise to
drug resistance is present in said polynucleic acids.
3. Method according to claim 2 further characterized in that said
primer pair is chosen from the following primers: SEQ ID NO: 3, SEQ
ID NO: 503, SEQ ID NO: 504, SEQ ID NO: 4, SEQ ID NO: 506, SEQ ID
NO: 507, SEQ ID NO: 508 and SEQ ID NO: 509.
4. The method of claim 2 wherein step b) comprises amplifying a
fragment of the protease gene with at least one 5'-primer
specifically hybridizing to a target sequence located at nucleotide
position 210 to 260 of the coding portion of the protease gene, in
combination with at least one suitable 3'-primer.
5. The method of claim 2 wherein step b) comprises amplifying a
fragment of the protease gene with at least one 3'-primer
specifically hybridizing to a target sequence located at nucleotide
position 253 (codon 85) to position 300 of the coding portion of
the protease gene, in combination with at least one suitable
5'-primer.
6. Method according to claim 4, further characterized in that the
5'-primer is SEQ ID NO: 5 and the 3'-primer is one primer or a
combination of primers chosen from the following primers: SEQ ID
NO: 4, SEQ ID NO: 506, SEQ ID NO: 507, SEQ ID NO: 508 and SEQ ID
NO: 509.
7. Method according to claim 5, further characterized in that the
5'-primer is one primer or a combination of primer chosen from the
following primers: SEQ ID NO: 3, SEQ ID NO: 503, SEQ ID NO: 504 and
the 3'-primer is SEQ ID NO: 6.
8. The method according to claim 1 wherein said primer pair is
chosen from the following primers: SEQ ID NO: 3, SEQ ID NO: 503,
SEQ ID NO: 504, SEQ ID NO: 4, SEQ ID NO: 506, SEQ ID NO: 507, SEQ
ID NO: 508 and SEQ ID NO: 509.
9. The method of claim 1 wherein step b) comprises amplifying a
fragment of the protease gene with at least one 5'-primer
specifically hybridizing to a target sequence located at nucleotide
position 210 to 260 of the coding portion of the protease gene, in
combination with at least one suitable 3'-primer.
10. The method of claim 1 wherein step b) comprises amplifying a
fragment of the protease gene with at least one 3'-primer
specifically hybridizing to a target sequence located at nucleotide
position 253 (codon 85) to position 300, in combination with at
least one suitable 5'-primer.
11. The method of claim 1 wherein the target sequences for codon
82/84 are provided by SEQ ID NO: 228-357.
Description
1. FIELD OF THE INVENTION
The present invention relates to the field of HIV diagnosis. More
particularly, the present invention relates to the field of
diagnosing the susceptibility of an HIV sample to antiviral drugs
used to treat HIV infection.
The present invention relates to a method for the rapid and
reliable detection of drug-selected mutations in the HIV protease
gene allowing the simultaneous characterization of a range of
codons involved in drug resistance using specific sets of probes
optimized to function together in a reverse-hybridization
assay.
2. BACKGROUND OF THE INVENTION
The human immunodeficiency virus (HIV) is the ethiological agent
for the acquired immunodeficiency syndrome (AIDS). HIV, like other
retroviruses, encodes an aspartic protease that mediates the
maturation of the newly produced viral particle by cleaving viral
polypeptides into their functional forms (Hunter et al). The HIV
protease is a dimeric molecule consisting of two identical subunits
each contributing a catalytic aspartic residue (Navia et al,
Whodawer et al, Meek et al). Inhibition of this enzyme gives rise
to noninfectious viral particles that cannot establish new cycles
of viral replication (Kohl et al, Peng et al).
Attempts to develop inhibitors of HIV-1 protease were initially
based on designing peptide compounds that mimicked the natural
substrate. The availability of the 3-dimensional structure of the
enzyme have more recently allowed the rational design of protease
inhibitors (PI) using computer modeling (Huff et al, Whodawer et
al). A number of second generation PI that are partially peptidic
or entirely nonpeptidic have proven to exhibit particularly potent
antiviral effects in cell culture. Combinations of various protease
inhibitors with nucleoside and non-nucleoside RT inhibitors have
also been studied extensively in vitro. In every instance, the
combinations have been at least additive and usually
synergistic.
In spite of the antiviral potency of many recently developed HIV-1
PI, the emergence of virus variants with decreased sensitivity to
these compounds has been described both in cell culture and in
treated patients thereby escaping the inhibitory effect of the
antiviral (Condra et al.). Emergence of resistant variants depends
on the selective pressure applied to the viral population. In the
case of a relatively ineffective drug, selective pressure is low
because replication of both wild-type virus and any variants can
continue. If a more effective drug suppresses replication of virus
except for a resistant variant, then that variant will be selected.
Virus variants that arise from selection by PI carry several
distinct mutations in the protease coding sequence that appear to
emerge sequentially. A number of these cluster near the active site
of the enzyme while others are found at distant sites. This
suggests conformational adaptation to primary changes in the active
site and in this respect certain mutations that increase resistance
to PI also decrease protease activity and virus replication.
Amongst the PI, the antiviral activity of the PI ritonavir
(A-75925; ABT-538). nelfinavir (AG-1343), indinavir (MK-639; L735;
L524) and saquinavir (Ro 31-8959) have been approved by the Food
and Drug Administration and are currently under evaluation in
clinical trials involving HIV-infected patients. The VX-487
(141W94) antiviral compound is not yet approved. The most important
mutations selected for the above compounds and leading to gradually
increasing resistance are found at amino acid (aa) positions 30 (D
to N), 46 (M to I), 48 (G to V), 50 (I to V), 54 (I to A, I to V),
82 (V to A, or F, or I, or T), 84 (I to V) and 90 (L to M). Other
mutations associated with drug resistance to the mentioned
compounds have been described (Schinazi et al).
Saquinavir-resistant variants, which usually carry mutations at
amino acid positions 90 and/or 48, emerge in approximately 45% of
patients after 1 year of monotherapy. Resistance appears to develop
less frequently with higher doses of saquinavir. Resistance to
indinavir and ritonavir requires multiple mutations; usually at
greater than 3 and up to 11 sites, with more amino acid
substitutions conferring higher levels of resistance. Resistant
isolates usually carry mutations at codons 82, 84, or 90. In the
case of ritonavir, the mutation at codon 82 appears fist in most
patients. Although mutant virions resistant to saquinavir are not
cross-resistant to indinavir or ritonavir, isolates resistant to
indinavir are generally ritonavir resistant and visa versa.
Resistance to either indinavir or ritonavir usually results in
cross-resistance to saquinavir. Approximately one third of
indinavir resistant isolates are cross-resistant to nelfinavir as
well.
The regime for an efficient antiviral treatment is currently not
clear at all. Patterns of reduced susceptibility to HIV protease
inhibitors have been investigated in vitro by cultivating virus in
the presence of PI. These data, however, do not completely predict
the pattern of amino-acid changes actually seen in patients
receiving PI. Knowledge of the resistance and cross-resistance
patterns should facilitate selection of optimal drug combinations
and selection of sequences with non-overlapping resistance
patterns. This would delay the emergence of cross-resistant viral
strains and prolong the duration of effective antiretroviral
activity in patients. Therefore, there is need for methods and
systems that detect these mutational events in order to give a
better insight into the mechanisms of HIV resistance. Further,
there is need for methods and systems which can provide data
important for the antiviral therapy to follow in a more
time-efficient and economical manner compared to the conventional
cell-culture selection techniques.
3. AIMS OF THE INVENTION
It is an aim of the present invention to develop a rapid and
reliable detection method for determination of the antiviral drug
resistance of viruses, which contain protease genes such as HIV
retroviruses present in a biological sample.
More particularly it is an aim of the present invention to provide
a genotyping assay allowing the detection of the different HIV
protease gene wild type and mutation codons involved in the
antiviral resistance in one single experiment.
It is also an aim of the present invention to provide an HIV
protease genotyping assay or method which allows to infer the
nucleotide sequence at codons of interest and/or the amino acids at
the codons of interest and/or the antiviral drug selected spectrum,
and possibly also infer the HIV type or subtype isolate
involved.
Even more particularly it is an aim of the present invention to
provide a genotyping assay allowing the detection of the different
HIV protease gene polymorphisms representing wild-type and mutation
codons in one single experimental setup.
It is another aim of the present invention to select particular
probes able to discriminate wild-type HIV protease sequences from
mutated or polymorphic HIV protease sequences conferring resistance
to one or more antiviral drugs, such as ritonavir (A-75925;
ABT-538), nelfinavir (AG-1343), indinavir (MK-639; L735; L524),
saquinavir (Ro 31-8959) and VX-478 (141W94) or others (Shinazi et
al).
It is more particularly an aim of the present invention to select
particular probes able to discriminate wild-type HIV protease
sequences from mutated or polymorphic HIV protease sequences
conferring resistance to ritonavir (A-75925; ABT-538).
It is more particularly an aim of the present invention to select
particular probes able to discriminate wild-type HIV protease
sequences from mutated HIV protease sequences conferring resistance
to nelfinavir (AG-1343).
It is more particularly an aim of the present invention to select
particular probes able to discriminate wild-type HIV protease
sequences from mutated HIV protease sequences conferring resistance
to indinavir (MK-639; L735; L524).
It is more particularly an aim of the present invention to select
particular probes able to discriminate wild-type HIV protease
sequences from mutated HIV protease sequences conferring resistance
to saquinavir (Ro 31-8959).
It is more particularly an aim of the present invention to select
particular probes able to discriminate wild-type HIV protease
sequences from mutated HIV protease sequences conferring resistance
to VX-478 (141W94).
It is also an aim of the present invention to select particular
probes able to determine and/or infer cross-resistance to HIV
protease inhibitors.
It is more particularly an aim of the present invention to select
particular probes able to discriminate wild-type HIV protease from
mutated HIV protease sequences involving at least one of amino acid
positions 30 (D to N), 46 (M to I), 48 (G to V), 50 (I to V), 54 (I
to A or V), 82 (V to A or F or I or T), 84(I to V) and 90 (L to M)
of the viral protease gene.
It is particularly an aim of the present invention to select a
particular set of probes, able to discriminate wild-type HIV
protease sequences from mutated HIV protease sequences conferring
resistance to any of the antiviral drugs defined above with this
particular set of probes being used in a reverse hybridization
assay.
It is moreover an aim of the present invention to combine a set of
selected probes able to discriminate wild-type HIV protease
sequences from mutated HIV protease sequences conferring resistance
to antiviral drugs with another set of selected probes able to
identify the HIV isolate, type or subtype present in the biological
sample, whereby all probes can be used under the same hybridization
and wash-conditions.
It is also an aim of the present invention to select primers
enabling the amplification of the gene fragment(s) determining the
antiviral drug resistance trait of interest.
It is also an aim of the present invention to select particular
probes able to identify mutated HIV protease sequences resulting in
cross-resistance to antiviral drugs.
The preset invention also aims at diagnostic kits comprising said
probes useful for developing such a genotyping assay.
The present invention also aims at diagnostic kits comprising said
primers useful for developing such a genotyping assay.
4. DETAILED DESCRIPTION OF THE INVENTION
All the aims of the present invention have been met by the
following specific embodiments.
According to one embodiment, the present invention relates to a
method for determining the susceptibility to antiviral drugs of HIV
viruses in a biological sample, with said method comprising: a) if
need be, releasing, isolating or concentrating the polynucleic
acids present in the sample; b) if need be amplifying the relevant
part of the protease gene of HIV with at least one suitable primer
pair; c) hybridizing the polynucleic acids of step a) or b) with at
least one of the following probes: probes specifically hybridizing
to a target sequence comprising codon 30; probes specifically
hybridizing to a target sequence comprising codon 46 and/or 48;
probes specifically hybridizing to a target sequence comprising
codon 50; probes specifically hybridizing to a target sequence
comprising codon 54; probes specifically hybridizing to a target
sequence comprising codon 82 and/or 84; probes specifically
hybridizing to a target sequence comprising codon 90; or the
complement of said probes, further characterized in that said
probes specifically hybridize to any of the target sequences
presented in FIG. 1, or to the complement of said target sequences;
d) inferring from the result of step c) whether or not a mutation
giving rise to drug resistance is present in any of said target
sequences.
The numbering of HIV-1 protease gene encoded amino acids is as
generally accepted in literature. Mutations that give rise to an
amino acid change at position 48 or 90 are known to confer
resistance to saquinavir (Eriebe et al; Tisdale et al). An amino
acid change at codon 46 or 54 or 82 or 84 results in ritonavir and
indinavir resistance (Kempf et al; Emini et al; Condra et al).
Amino acid changes at positions 30 and 46 confer resistance to
nelfinavir (Patick et al) and amino acid changes at position 50
confers resistance to VX-487 (Rao et al). Therefore, the method
described above allows to determine whether a HIV strain is
susceptible or resistant to any of the drugs mentioned above. This
method can be used, for instance, to screen for mutations
conferring resistance to any of the mentioned drugs before
initiating therapy. This method may also be used to s for mutations
that may arise during the course of therapy (i.e. monitoring of
drug therapy). It is obvious that this method may also be used to
determine resistance to drugs other than the above-mentioned drugs,
provided that resistance to these other drugs is linked to
mutations that can be detected by use of this method. This method
may also be used for the specific detection of polymorphic
nucleotides. It is to be understood that the said probes may only
partly overlap with the targets sequences of FIG. 1, table 2 and
table 3, as long as they allow for specific detection of the
relevant polymorphic nucleotides as indicated above. The sequences
of FIG. 1, table 2 and table 3 were derived from polynucleic acid
fragments comprising the protease gene. These fragments were
obtained by PCR amplification and were inserted into a cloning
vector and sequence analyzed as described in example 1. It is to be
noted that some polynucleic acid fragments comprised polymorphic
nucleotides in their sequences, which have not been previously
disclosed. These novel polymorphic nucleotide sequences are
represented in table 4 below.
The present invention thus also relates to these novel sequences,
or a fragment thereof, wherein said fragment consists of at least
10, preferably 15, even more preferably 20 contiguous nucleotides
and contains at least one polymorphic nucleotide. It is furthermore
to be understood that these new polymorphic nucleotides may also be
expected to arise in another sequence context than in the mentioned
sequences. For instance a G at the third position of codon 55 is
shown in SEQ ID N.sup.o 478 m combination with a T at the third
position of codon 54, but a G at the third position of codon 55 may
also be expected to occur in the context of a wild type sequence.
It is also to be understood that the above mentioned specifications
apply to the complement of the said target sequences as well. This
applies also to FIG. 1.
According to a preferred embodiment the present invention relates
to a method as indicated above, further characterized in that said
probes are capable of simultaneously hybridizing to their
respective target regions under appropriate hybridization and wash
conditions allowing the detection of the hybrids formed.
According to a preferred embodiment, step c is performed using a
set of at least 2, preferably at least 3, more preferably at least
4 and most preferably at least 5 probes meticulously designed as
such that they show the desired hybridization results. In general
this method may be used for any purpose that relies on the presence
or absence of mutations that can be detected by this method, e.g.
for genotyping. The probes of table 1 have been optimized to give
specific hybridization results when used in a LiPA assay (see
below), as described in examples 2 and 3. These probes have thus
also been optimized to simultaneously hybridize to their respective
target regions under the same hybridization and wash conditions
allowing the detection of hybrids. The sets of probes for each of
the codons 30,46/48, 50, 54 and 82/84 have been tested
experimentally as described in examples 2 and 3. The reactivity of
the sets shown in table 1 with 856 serum samples from various
geographic origins was evaluated. It was found that the sets of
probes for codons 30, 46/48, 50, 54 and 82/84 reacted with 98.9%,
99.6%, 98.5%, 99.20%, 95.4% and 97.2% of the test samples,
respectively. The present invention thus also relates to the sets
of probes for codons 30, 46/48, 50, 54, 82/84 and 90, shown in
table 1 and table 7.
According to another even more preferred embodiment, the present
invention relates to a method as defined above, further
characterized in that: step b) comprises amplifying a fragment of
the protease gene with at least one 5'-primer specifically
hybridizing to a target sequence located between nucleotide
position 210 and nucleotide position 260 (codon 87), more
preferably between nucleotide position 220 and nucleotide position
260 (codon 87), more preferably between nucleotide position 230 and
nucleotide position 260 (codon 87), even more preferably at
nucleotide position 241 to nucleotide position 260 (codon 87) in
combination with at least one suitable 3'-primer, and step c)
comprises hybridizing the polynucleic acids of step a) or b) with
at least one of the probes specifically hybridizing to a target
sequence comprising codon 90.
According to another even more preferred embodiment, the present
invention relates to a method as defined above, further
characterized in that: step b) comprises amplifying a fragment of
the protease gene with at least one 3'-primer specifically
hybridizing to a target sequence located between nucleotide
position 253 (codon 85) and nucleotide positions 300, more
preferably between nucleotide position 253 (codon 85) and
nucleotide positions 290, more preferably between nucleotide
position 253 (codon 85) and nucleotide positions 280, even more
preferably at nucleotide position 253 (codon 85) to nucleotide
position 273 (codon 91), in combination with at least one suitable
5'-primer, and step c) comprises hybridizing the polynucleic acids
of step a) or b) with at least one of the probes specifically
hybridizing to a target sequence comprising any of codons 30, 46,
48, 50, 52, 54, 82 and 84.
It has been found, unexpectedly, that an amplified nucleic acid
fragment comprising all of the above-mentioned codons, does not
hybridize optimally to probes comprising codon 82, 84 or 90. On the
other hand, a shorter fragment, for instance the fragment which is
amplified by use of the primers Prot41bio and Prot6bio with
respectively seq id no 5 and seq id no 4; hybridizes better to
probes comprising codon 90. Better hybridization is also obtained
when the fragment is amplified with primer Prot41bio in combination
with primers Prot6abio, Prot6bbio, Prot6cbio and Prot6dbio. The
present invention thus also relates to a method as defined above,
finder characterized in that the 5'-primer is seq id no 5 and at
least one 3' primer is chosen from seq id no 4, seq id no506, seq
id no 507, seq id no 508, and seq id 509. Likewise, another shorter
fragment, for instance the fragment which is amplified by use of
the primers Prot2bio and Prot31bio with respectively seq id no 3
and seq id no 6, was found to hybridize better to probes comprising
codon 82 and/or 84. Hence the present invention also relates to a
method as defined above, further characterized in that the
5'-primer is seq id no 5 and at least one 3'-primer is chosen from
seq id no 4, seq id no506, seq id no 507, seq id no 508, and seq id
no 509.
New sets of amplification primers as mentioned in example 1 were
selected. The present invention thus also relates to primers:
prot16 (SEQ ID NO 501), prot5 (SEQ ID NO 5), prot2abio (SEQ ID NO
503), prot2bbio (SEQ ID NO 504), prot31bio (SEQ ID NO 6),
prot41-bio (SEQ ID NO 505), prot6a (SEQ ID NO 506), prot6b (SEQ ID
NO 507), prot6c (SEQ ID NO 508) and prot6d (SEQ DID NO 509). A
number of these primers are chemically modified (biotinylated),
others are not. The present invention relates to any of the primers
mentioned, primers containing unmodified nucleotides, or primers
containing modified nucleotides.
Different techniques can be applied to perform the
sequence-specific hybridization methods of the present invention.
These techniques may comprise immobilizing the amplified HIV
polynucleic acids on a solid support and performing hybridization
with labeled oligonucleotide probes. HIV polynucleic acids may also
be immobilized on a solid support without prior amplification and
subjected to hybridization. Alternatively, the probes may be
immobilized on a solid support and hybridization may be performed
with labeled HIV polynucleic acids, preferably after amplification.
This technique is called reverse hybridization. A convenient
reverse hybridization technique is the line probe assay (LiPA).
This assay uses oligonucleotide probes immobilized as parallel
lines on a solid support strip (Stuyver et al., 1993). It is to be
understood that any other technique based on the above-mentioned
methods is also covered by the present invention.
According to another preferred embodiment, the present invention
relates to any of the probes mentioned above and/or to any of the
primers mentioned above, with said primers and probes being
designed for use in a method for determining the susceptibility to
antiviral drugs of HIV viruses in a sample. According to an even
more preferred embodiment, the present invention relates to the
probes with seq id no 7 to seq id no 477 and seq id no510 to seq id
no 519, more preferably to the seq id no mentioned in Table 1 and
Table 7, and to the primers with seq id no 3, 4, 5 and 6, 501, 502,
503, 504, 505, 506, 507, 508 and 509. The skilled man will
recognize that addition or deletion of one or more nucleotides at
their extremities may adapt the said probes and primers. Such
adaptations may be requited if the conditions of amplification or
hybridization are changed, or if the amplified material is RNA
instead of DNA, as is the case in the NASBA system
According to another preferred embodiment, the present invention
relates to a diagnostic kit enabling a method for determining the
susceptibility to antiviral drugs of HIV viruses in a biological
sample, with said kit comprising: a) when appropriate, a means for
releasing, isolating or concentrating the polynucleic acids present
in said sample; b) when appropriate, at least one of the primers of
any of claims 4 to 6; c) at least one of the probes of any of
claims 1 to 3, possibly fixed to a solid support; d) a
hybridization buffer, or components necessary for producing said
buffer; e) a wash solution, or components necessary for producing
said solution; f) when appropriate, a means for detecting the
hybrids resulting from the preceding hybridization; h) when
appropriate, a means for attaching said probe to a solid
support.
DEFINITIONS
The following definitions serve to illustrate the terms and
expressions used in the present invention.
The term "antiviral drugs" refers particularly to any antiviral
protease inhibitor. Examples of such antiviral drugs and the
mutation they may cause in the HIV protease gene are disclosed in
Schinazi et al., 1997. The contents of the latter two documents
particularly are to be considered as forming part of the present
invention. The most important antiviral drugs focussed at in the
present invention are disclosed in Tables 1 to 2.
The target material in the samples to be analyzed may either be DNA
or RNA, e.g.: genomic DNA, messenger RNA, viral RNA or amplified
versions thereof. These molecules are also termed polynucleic
acids.
It is possible to use genomic DNA or RNA molecules from HIV samples
in the methods according to the present invention.
Well-known extraction and purification procedures are available for
the isolation of RNA or DNA from a sample (fi. in Maniatis et al.,
Molecular Cloning: A Laboratory Manual, 2nd Edition, Cold Spring
Harbour Laboratory Press (1989)).
The term "probe" refers to single stranded sequence-specific
oligonucleotides, which have a sequence, which is complementary to
the target sequence to be detected.
The term "target sequence" as referred to in the present invention
describes the wild type nucleotide sequence, or the sequence
comprising one or more polymorphic nucleotides of the protease gene
to be specifically detected by a probe according to the present
invention. This nucleotide sequence may encompass one or several
nucleotide changes. Target sequences may refer to single nucleotide
positions, codon positions, nucleotides encoding amino acids or to
sequences spanning any of the foregoing nucleotide positions. In
the present invention said target sequence often includes one or
two variable nucleotide positions.
The term "polymorphic nucleotide" indicates a nucleotide in the
protease gene of a particular HIV virus that is different from the
nucleotide at the corresponding position in at least one other HIV
virus. The polymorphic nucleotide may or may not give rise to
resistance to an antiviral drug. It is to be understood that the
complement of said target sequence is also a suitable target
sequence in some cases. The target sequences as defined in the
present invention provide sequences which should be complementary
to the central part of the probe which is designed to hybridize
specifically to said target region.
The term "complementary" as used herein means that the sequence of
the single stranded probe is exactly the (inverse) complement of
the sequence of the single-stranded target, with the target being
defined as the sequence where the mutation to be detected is
located.
"Specific hybridization" of a probe to a target sequence of the HIV
polynucleic acids means that said probe forms a duplex with part of
this region or with the entire region under the experimental
conditions used, and that under those conditions said probe does
not form a duplex with other regions of the polynucleic acids
present in the sample to be analyzed.
Since the current application requires the detection of single
basepair mismatches, very stringent conditions for hybridization
are required, allowing in principle only hybridization of exactly
complementary sequences. However, variations arm possible in the
length of the probes (see below), and it should be noted that,
since the central part of the probe is essential for its
hybridization characteristics, possible deviations of the probe
sequence versus the target sequence may be allowable towards head
and tail of the probe, when longer probe sequences are used. These
variations, which may be conceived from the common knowledge in the
art, should however always be evaluated experimentally, in order to
check if they result in equivalent hybridization characteristics
than the exactly complementary probes.
Preferably, the probes of the invention are about 5 to 50
nucleotides long, more preferably from about 10 to 25 nucleotides.
Particularly preferred lengths of probes include 10, 11, 12, 13,
14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or 25 nucleotides. The
nucleotides as used in the present invention may be
ribonucleotides, deoxyribonucleotides and modified nucleotides such
as inosine or nucleotides containing modified groups, which do not
essentially alter their hybridization characteristics.
Probe sequences are represented throughout the specification as
single stranded DNA oligonucleotides from the 5' to the 3' end. It
is obvious to the man skilled in the art that any of the
below-specified probes can be used as such, or in their
complementary form, or in their RNA form (wherein U replaces
T).
The probes according to the invention can be prepared by cloning of
recombinant plasmids containing inserts including the corresponding
nucleotide sequences, if need be by cleaving the latter out from
the cloned plasmids upon using the adequate nucleases and
recovering them, e.g. by fractionation according to molecular
weight. The probes according to the present invention can also be
synthesized chemically, for instance by the conventional
phospho-triester method.
The term "solid support" can refer to any substrate to which an
oligonucleotide probe can be coupled, provided that it retains its
hybridization characteristics and provided that the background
level of hybridization remains low. Usually the solid substrate
will be a microtiter plate, a membrane (e.g. nylon or
nitrocellulose) or a microsphere (bead) or a chip. Prior to
application to the membrane or fixation it may be convenient to
modify the nucleic acid probe in order to facilitate fixation or
improve the hybridization efficiency. Such modifications may
encompass homopolymer tailing, coupling with different reactive
groups such as aliphatic groups, NH.sub.2 groups, SH groups,
carboxylic groups, or coupling with biotin, haptens or
proteins.
The term "labeled" refers to the use of labeled nucleic acids.
Labeling may be carried out by the use of labeled nucleotides
incorporated during the polymerase step of the amplification such
as illustrated by Saiki et al. (1988) or Bej et al. (1990) or
labeled primers, or by any other method known to the person skilled
in the art. The nature of the label may be isotopic (.sup.32 P,
.sup.35 S, etc.) or non-isotopic (biotin, digoxigenin, etc.).
The term "primer" refers to a single stranded oligonucleotide
sequence capable of acting as a point of initiation for synthesis
of a primer extension product, which is complementary to the
nucleic acid strand to be copied. The length and the sequence of
the primer must be such that they allow to prime the synthesis of
the extension products. Preferably the primer is about 5-50
nucleotides long. Specific length and sequence will depend on the
complexity of the required DNA or RNA targets, as well as on the
conditions of primer use such as temperature and ionic
strength.
The term "primer pair" refers to a set of primers comprising at
least one 5' primer and one 3' primer. The primer pair may consist
of more than two primers, the complexity of the number of primers
will depend on the hybridization conditions, variability of the
sequences in the regions to be amplified and the target sequences
to be detected.
The fact that amplification primers do not have to match exactly
with the corresponding template sequence to warrant proper
amplification is amply documented in the literature (Kwok et al.,
1990).
The amplification method used can be either polymerase chain
reaction (PCR; Saiki et al., 1988), ligase chain reaction (LCR;
Landgren et al., 1988; Wu & Wallace, 1989; Barany, 1991),
nucleic acid sequence-based amplification (NASBA; Guatelli et al.,
1990; Compton, 1991), transcription-based amplification system
(TAS; Kwoh et al., 1989), strand displacement amplification (SDA;
Duck, 1990) or amplification by means of QB replicase (Lomeli et
al., 1989) or any other suitable method to amplify nucleic acid
molecules known in the art.
The oligonucleotides used as primers or probes may also comprise
nucleotide analogues such as phosphorothiates (Matsukura et al.,
1987), alkylphosphorothiates (Miller et al., 1979) or peptide
nucleic acids (Nielsen et al., 1991; Nielsen et al., 1993) or may
contain intercalating agents (Asseline et al., 1984).
As most other variations or modifications introduced into the
original DNA sequences of the invention these variations will
necessitate adaptations with respect to the conditions under which
the oligonucleotide should be used to obtain the required
specificity and sensitivity. However the eventual results of
hybridization will be essentially the same as those obtained with
the unmodified oligonucleotides.
The introduction of these modifications may be advantageous in
order to positively influence characteristics such as hybridization
kinetics, reversibility of the hybrid-formation, biological
stability of the oligonucleotide molecules, etc.
The "sample" may be any biological material taken either directly
from the infected human being (or animal), or after culturing
(enrichment). Biological material may be e.g. expectorations of any
kind, broncheolavages, blood, skin tissue, biopsies, sperm,
lymphocyte blood culture material, colonies, liquid cultures, fecal
samples, urine etc.
The sets of probes of the present invention will include at least
2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20,
21, 22, 23, 24, 25, 26, 27, 28, 29, 30 or more probes. Said probes
may be applied in two or more distinct and known positions an a
solid substrate. Often it is preferable to apply two or more probes
together in one and the same position of said solid support.
For designing probes with desired characteristics, the following
useful guidelines known to the person skilled in the art can be
applied.
Because the extent and specificity of hybridization reactions such
as those described herein are affected by a number of factors,
manipulation of one or more of those factors will determine the
exact sensitivity and specificity of a particular probe, whether
perfectly complementary to its target or not. The importance and
effect of various assay conditions, explained further herein, are
known to those skilled in the art.
The stability of the [probe:target] nucleic acid hybrid should be
chosen to be compatible with the assay conditions. This may be
accomplished by avoiding long AT-rich sequences, by terminating the
hybrids with G:C base pairs, and by designing the probe with an
appropriate Tm. The beginning and end points of the probe should be
chosen so that the length and % GC result in a Tm about
2-10.degree. C. higher than the temperature at which the final
assay will be performed. The base composition of the probe is
significant because G-C base pairs exhibit greater thermal
stability as compared to A-T base pairs due to additional hydrogen
bonding. Thus, hybridization involving complementary nucleic acids
of higher G-C content will be stable at higher temperatures.
Conditions such as ionic strength and incubation temperature under
which a probe will be used should also be taken into account when
designing a probe. It is known that hybridization will increase as
the ionic strength of the reaction mixture increases, and that the
thermal stability of the hybrids will increase with increasing
ionic strength. On the other hand, chemical reagents, such as
formamide, urea, DMSO and alcohols, which disrupt hydrogen bonds,
will increase the stringency of hybridization. Destabilization of
the hydrogen bonds by such reagents can greatly reduce the Tm. In
general, optimal hybridization for synthetic oligonucleotide probes
of about 10-50 bases in length occurs approximately 5.degree. C.
below the melting temperature for a given duplex. Incubation at
tempts below the optimum may allow mismatched base sequences to
hybridize and can therefore result in reduced specificity.
It is desirable to have probes, which hybridize only under
conditions of high stringency. Under high stringency conditions
only highly complementary nucleic acid hybrids will form; hybrids
without a sufficient degree of complementarity will not form.
Accordingly, the stringency of the assay conditions determines the
amount of complementarity needed between two nucleic acid strands
forming a hybrid. The degree of stringency is chosen such as to
maximize the difference in stability between the hybrid formed with
the target and the nontarget nucleic acid. In the present case,
single base pair changes need to be detected, which requires
conditions of very high stringency.
The length of the target nucleic acid sequence and, accordingly,
the length of the probe sequence can also be important. In some
cases, there may be several sequences from a particular region,
varying in location and length, which will yield probes with the
desired hybridization characteristics. In other cases, one sequence
may be significantly better than another that differs merely by a
single base. While it is possible for nucleic acids that are not
perfectly complementary to hybridize, the longest stretch of
perfectly complementary base sequence will normally primarily
determine hybrid stability. While oligonucleotide probes of
different lengths and base composition may be used, preferred
oligonucleotide probes of this invention arm between about 5 to 50
(more particularly 10-25) bases in length and have a sufficient
stretch in the sequence which is perfectly complementary to the
target nucleic acid sequence.
Regions in the target DNA or RNA, which are known to form strong
internal structures inhibitory to hybridization, arc less
preferred. Likewise, probes with extensive self-complementarity
should be avoided. As explained above, hybridization is the
association of two single strands of complementary nucleic acids to
form a hydrogen bonded double strand. It is implicit that if one of
the two strands is wholly or partially involved in a hybrid that it
will be less able to participate in formation of a new hybrid.
There can be intramolecular and intermolecular hybrids formed
within the molecules of one type of probe if there is sufficient
self complementarity. Such structures can be avoided through
careful probe design. By designing a probe so that a substantial
portion of the sequence of interest is single stranded, the rate
and extent of hybridization may be greatly increased. Computer
programs are available to search for this type of interaction.
However, in certain instances, it may not be possible to avoid this
type of interaction.
Standard hybridization and wash conditions are disclosed in the
Materials & Methods section of the Examples. Other conditions
are for instance 3.times.SSC (Sodium Saline Citrate), 20% deionized
FA (Formamide) at 50.degree. C.
Other solutions (SSPE (Sodium saline phosphate EDTA), TMACl
(tetramethyl ammonium Chloride), etc.) and temperatures can also be
used provided that the specificity and sensitivity of the probes is
maintained. If need be, slight modifications of the probes in
length or in sequence have to be carried out to maintain the
specificity and sensitivity required under the given
circumstances.
Primers may be labeled with a label of choice (e.g. biotin).
Different primer-based target amplification systems may be used,
and preferably PCR-amplification, as set out in the examples.
Single-round or nested PCR may be used.
The term "hybridization buffer" means a buffer enabling a
hybridization reaction to occur between the probes and the
polynucleic acids present in the sample, or the amplified product,
under the appropriate stringency conditions.
The term "wash solution" means a solution enabling washing of the
hybrids formed under the appropriate stringency conditions.
The following examples only serve to illustrate the present
invention. These examples are in no way intended to limit the scope
of the present invention.
FIGURE AND TABLE LEGENDS
FIG. 1: Natural and drug selected variability in the vicinity of
codons 30, 46, 48, 50, 54, 82, 84, and 90 of the HIV-1 protease
gene. The most frequently observed wild-type sequence is shown in
the top line (SEQ ID NO: 520 for codon 30, SEQ ID NO: 521 for codon
46/48, SEQ ID NO: 522 for codon 50, SEQ ID NO: 523 for codon for
codon 54, SEQ ID NO: 524 for codon 82/84, and SEQ ID NO: 525 for
codon 90). Naturally occurring variations are indicated below and
occur independently from each other. Variants sequences for each of
the indicated codons are as follows: SEQ ID NO: 7-46 for codon 30,
SEQ ID NO: 47-120 for codon 46/48, SEQ ID NO: 121-175 for codon 50,
SEQ ID NO: 176-227 for codon 54, SEQ ID NO: 228-357 for codon
82/84, and SEQ ID NO: 358-477 for codon 90. Drug-selected variants
are indicated in bold.
FIG. 2A: Reactivities of the selected probes for codon 30
immobilized on LiPA strips with reference material. The information
in the boxed surface is not relevant for the discussion of probes
for codon 30. The position of each selected probe on the membrane
strip is shown at the left of each panel. The sequence of the
relevant part of the selected probes is shown at the left and is
given in Table 1. Each strip is incubated with a biotinylated PCR
fragment from the reference panel. The reference panel accession
numbers are indicated in Table 1 (SEQ ID NO: 31 corresponds to w25,
SEQ ID NO: 35 corresponds to w29, SEQ ID NO: 32 corresponds to w32,
SEQ ID NO: 42 corresponds to w36, and SEQ ID NO: 29 corresponds to
m23). For several probes multiple reference panel possibilities are
available, but only one relevant accession number given each time.
*: False positive reactivities. At the bottom the strips, the amino
acids at the relevant codon, as derived from the probe reactivity,
is indicated.
FIG. 2B: Reactivities of the selected probes for codons 46 and 48
immobilized on LiPA strips with reference material. The information
in the boxed surface is not relevant for the discussion of probes
for codons 46 and 48. The position of each selected probe on the
membrane strip is shown at the left of each panel. The sequence of
the relevant part of the selected probes is given in Table 1. Each
strip is incubated with a biotinylated PCR fragment from the
reference panel. The reference panel accession numbers are
indicated in Table 1 (SEQ ID NO: 93 corresponds to w47, SEQ ID NO:
91 corresponds to w45, SEQ ID NO: 120 corresponds to w72, and SEQ
ID NO: 87 corresponds to m41). For several probes multiple
reference panel possibilities are available, but only one relevant
accession number given each time. *: False positive reactivities.
On top of the strips, the amino acids at the relevant codon, as
derived from the probe reactivity, is indicated.
FIG. 2C: Reactivities of the selected probes for codon 50
immobilized on LiPA strips With reference material. The information
in the boxed surface is not relevant for the discussion of probes
for codon 50. The position of each selected probe on the membrane
strip is shown at the left of each panel. The sequence of the
relevant part of the selected probes is given in Table 1. Each
strip is incubated with a biotinylated PCR fragment from the
reference panel. The reference panel accession numbers are
indicated in Table 1 (SEQ ID NO: 151 corresponds to w31, SEQ ID NO:
164 corresponds to w44, SEQ ID NO: 172 corresponds to w51, and SEQ
ID NO: 157 corresponds to m37). For several probes multiple
reference panel possibilities are available, but only one relevant
accession number given each time. *: False positive reactivities.
At the bottom of the strips, the amino acids at the relevant codon,
as derived from the probe reactivity, is indicated.
FIG. 2D: Reactivities of the selected probes for codon 54
immobilized on LiPA strips with reference material. The information
in the boxed surface is not relevant for the discussion of probes
for codon 54. The position of each selected probe on the membrane
strip is shown at the left of each panel. The sequence of the
relevant part of the selected probes is given in Table 1. Each
strip is incubated with a biotinylated PCR fragment from the
reference panel. The reference panel accession numbers are
indicated in Table 1 (SEQ ID NO: 178 corresponds to w3, SEQ ID NO:
212 corresponds to w34, SEQ ID NO: 189 corresponds to w14, SEQ ID
NO: 194 corresponds to w19, SEQ ID NO: 197 corresponds to w22, SEQ
ID NO: 202 corresponds to w26, SEQ ID NO: 204 corresponds to w27,
SEQ ID NO: 213 corresponds to m35, and SEQ ID NO: 215 corresponds
to m37). For several probes multiple reference panel possibilities
are available, but only one relevant accession number given each
time. *: False positive reactivities. At the bottom of the strips,
the amino acids at the relevant codon, as derived from the probe
reactivity, is indicated.
FIG. 2E: Reactivities of the selected probes for codons 82 and 84
immobilized on LiPA strips with reference material. The information
in the boxed surface is not relevant for the discussion of probes
for codons 82 and 84. The position of each selected probe on the
membrane strip is shown at the left of each panel. The sequence of
the relevant part of the selected probes is given in Table 1. Each
strip is incubated with a biotinylated PCR fragment from the
reference panel. The reference panel accession numbers are
indicated in Table 1 (SEQ ID NO: 318 corresponds to w91, SEQ ID NO:
287 corresponds to w60, SEQ ID NO: 338 corresponds to w111, SEQ ID
NO: 316 corresponds to w89, SEQ ID NO: 269 corresponds to w42 SEQ
ID NO: 263 corresponds to m36, SEQ ID NO: 294 corresponds to m67.
SEQ ID NO: 265 corresponds to m38, SEQ ID NO: 332 corresponds to
m105, SEQ ID NO: 354 corresponds to m127, SEQ ID NO: 267
corresponds to m40, SEQ ID NO: 290 corresponds to m63, and SEQ ID
NO: 328 corresponds to m101). For several probes multiple reference
panel possibilities are available, but only one relevant accession
number given each time. *: False positive reactivities. At the
bottom of the strips, the amino acids at the relevant codon, as
derived from the probe reactivity, is indicated.
FIG. 2F: Reactivities of the selected probes for codon 90
immobilized on LiPA strips with reference material. The information
in the boxed surface is not relevant for the discussion of probes
for codon 90. The position of each selected probe on the membrane
strip is shown at the left of each panel. The sequence of the
relevant part of the selected probes is given in Table 1. Each
strip is incubated with a biotinylated PCR fragment from the
reference panel. The reference panel accession numbers are
indicated in Table 1 (SEQ ID NO: 384 corresponds to w27, SEQ ID NO:
394 corresponds to w37, SEQ ID NO: 396 corresponds to w39, SEQ ID
NO: 407 corresponds to w50, SEQ ID NO: 409 corresponds to w52, SEQ
ID NO: 426 corresponds to w69, SEQ ID NO: 430 corresponds to w73,
SEQ ID NO: 436 corresponds to w79, SEQ ID NO: 400 corresponds to
m43, and SEQ ID NO: 413 corresponds to m56). For several probes
multiple reference panel possibilities are available, but only one
relevant accession number given each time. *: False positive
reactivities. At the bottom of the strips, the amino acids at the
relevant codon, as derived from the probe reactivity, is
indicated.
FIG. 3: Sequence and position of the HIV-1 protease amplification
primers. To obtain the reactivity with probes selected to determine
the susceptibility to antiviral drugs involving codons 30, 46, 48,
50, 54, 82, and 84, nested amplification primers prot2bio (5'
primer, SEQ ID NO: 526) and Prot31bio (3' primer, SEQ ID NO: 527)
were designed. To obtain the reactivity with probes selected to
determine the susceptibility to antiviral drugs involving codon 90,
nested amplification primers Prot41bio (5' primer, SEQ ID NO: 528)
and Prot6bio (3' primer, SEQ ID NO: 529) were designed.
FIG. 4A: Phylogenetic analysis on 312 protease sequences allowed to
separate genotype B strains from non-B strains. Reactivities of the
selected probes for codon 30 immobilized on LiPA strips with a
biotinylated PCR fragment of genotype B strains and non-B strains
is shown, the exact percentages are indicated in table 5. The
probes are indicated at the bottom. The sequence of the relevant
part of the probes is given in Table 1.
FIG. 4B: Phylogenetic analysis on 312 protease sequences allowed to
separate genotype B strains from non-B strains. Reactivities of the
selected probes for codons 46/48 immobilized on LiPA strips with a
biotinylated PCR fragment of genotype B strains and non-B strains
is shown, the exact percentages are indicated in table 5. The
probes are indicated at the bottom. The sequence of the relevant
part of the probes is given in Table 1.
FIG. 4C: Phylogenetic analysis on 312 protease sequences allowed to
separate genotype B strains from non-B strains. Reactivities of the
selected probes for codon 50 immobilized on LiPA strips with a
biotinylated PCR fragment of genotype B strains and non-B sons is
shown, the exact percentages are indicated in table 5. The probes
are indicated at the bottom. The sequence of the relevant part of
the probes is given in Table 1.
FIG. 4D: Phylogenetic analysis on 312 protease sequences allowed to
separate genotype B strains from non-B strains. Reactivities of the
selected probes for codon 54 immobilized on LiPA strips with a
biotinylated PCR fragment of genotype B strains and non-B stains is
shown, the exact percentages are indicated in table 5. The probes
are indicated at the bottom. The sequence of the relevant part of
the probes is given in Table 1.
FIG. 4E: Phylogenetic analysis on 312 protease sequences allowed to
separate genotype B strains from non-B strains. Reactivities of the
selected probes for codons 82/84 immobilized an LiPA strips with a
biotinylated PCR fragment of genotype B strains and non-B stains is
shown, the exact percentages are indicated in table 5. The probes
are indicated at the bottom. The sequence of the relevant part of
the probes is given in Table 1.
FIG. 4F: Phylogenetic analysis on 312 protease sequences allowed to
separate genotype B strains from non-B strains. Reactivities of the
selected probes for codon 90 immobilized on LiPA strips with a
biotinylated PCR fragment of genotype B strains and non-B strains
is shown, the exact percentages are indicated in table 5. The
probes are indicated at the bottom. The sequence of the relevant
part of the probes is given in Table 1.
FIG. 5A: Geographical origin of 856 samples and reactivities with
the different probes at codon position 30. The exact percentages
are indicated in table 6. The probes are indicated at the
bottom.
FIG. 5B: Geographical origin of 856 samples and reactivities with
the different probes at codon positions 46/48. The exact
percentages are indicated in table 6. The probes are indicated at
the bottom.
FIG. 5C: Geographical origin of 856 samples and reactivities with
the different probes at codon position 50. The exact percentages
arm indicated in table 6. The probes are indicated at the
bottom.
FIG. 5D: Geographical origin of 856 samples and reactivities with
the different probes at codon position 54. The exact percentages
arm indicated in table 6. The probes are indicated at the
bottom.
FIG. 5E: Geographical origin of 856 samples and reactivities with
the different probes at codon positions 82/84. The exact
percentages are indicated in table 6. The probes are indicated at
the bottom.
FIG. 5F: Geographical origin of 856 samples and reactivities with
the different probes at codon position 90. The exact percentages
are indicated in table 6. The probes are indicated at the
bottom.
Table 1: HIV-1 protease wild-type and drug-selected mutation probes
with their corresponding sequences as applied on the HIV-1 protease
LiPA strip. The most frequently observed wild-type sequence is
shown at the top line. Probe names corresponding to the selected
motifs are indicated in the left column, the relevant part of each
probe applied on the strip is shown under the consensus
sequence.
Table 2: Protease Inhibitors.
Table 3: HIV-1 protease wild-type and drug-selected mutation probes
with their corresponding sequences as synthesized, immobilized and
tested on LiPA strips. The most frequently observed wild-type
sequence is shown at the top line. Probe names corresponding to the
selected motifs arc indicated in the left column, the relevant part
of each probe applied on the strip is shown under the consensus
sequence. The probes retained are indicated in table 1.
Table 4: Polymorphic nucleotide sequences.
Table 5: % Reactivities of the HIV-1 protease wild-type and
drug-selected mutation probes applied on the HIV-1 protease LiPA
strip with genotype B strains and non-B strains.
Table 6: % Reactivities of the HIV-1 protease wild-type and
drug-selected mutation probes applied on the HIV-1 protease LiPA
strip with samples of different geographical origin.
Table 7: HIV-1 protease wild-type and drug-selected mutation probes
with their corresponding sequences as applied on the HIV-1 protease
LiPA strip. The most frequently observed wild-type sequence is
shown at the top line. Probe names corresponding to the selected
motifs are indicated in the left column, the relevant part of each
probe applied on the strip is shown under the consensus
sequence.
EXAMPLES
Example 1
Selection of the Plasma Samples, PCR Amplification and Cloning of
the PCR Products
Plasma samples (n=557) were taken from HIV type-1 infected patients
and stored at -20.degree. C. until use. Plasma samples were
obtained from naive and drug-treated patients. The drugs involved
ritonavr, indinavir and saquinavir. The serum samples were
collected from patients residing in Europe (Belgium, Luxembourg,
France, Spain and UK), USA and Brazil.
HIV RNA was prepared from these samples using the
guanidinium-phenol procedure. Fifty .mu.l plasma was mixed with 150
.mu.l Trizol.RTM.LS Reagent (Life Technologies, Gent, Belgium) at
room temperature (volume ratio: 1 unit sample/3 units Trizol).
Lysis and denaturation occurred by carefully pipetting up and down
several times, followed by an incubation step at room temperature
for at least 5 minutes. Fourthy .mu.l CHCl.sub.3 was added and the
mixture was shaken vigorously by hand for at least 15 seconds, and
incubated for 15 minutes at room temperature. The samples were
centrifuged at maximum 12,000 g for 15 minutes at 4.degree. C., and
the colorless aqueous phase was collected and mixed with 100 .mu.l
isopropanol. To visualize the minute amounts of viral RNA, 20 .mu.l
of 1 .mu.g/.mu.l Dextran T500 (Pharmacia) was added, mixed and left
at room temperature for 10 minutes. Following centrifugation at
max. 12,000 g for 10 minutes at 4.degree. C. and aspiration of the
supernatant, the RNA pellet was washed with 200 .mu.l ethanol,
mixed by vortexing and collected by centrifugation at 7,500 g for 5
minutes at 4.degree. C. Finally the RNA pellet was briefly
air-dried and stored at -20.degree. C. Alternatively, the High Pure
Viral Nucleic Acid Kit (Boehringer Mannheim ) was used to extract
RNA from the samples.
For cDNA synthesis and PCR amplification, the RNA pellet was
dissolved in 15 .mu.l random primes (20 ng/.mu.l, pdN.sub.6,
Pharmacia), prepared in DEPC-treated or HPLC grade water. After
denaturation at 70.degree. C. for 10 minutes, 5 .mu.l cDNA mix was
added, composed of 4 .mu.l 5.times. AMV-RT buffer (250 mM Tris.HCl
pH 8.5, 100 mM KCl, 30 mM MgCl.sub.2, 25 mM DTT)), 0.4 .mu.L 25 mM
dXTPs, 0.2 .mu.l or 25 U Ribonuclease Inhibitor (HPRI, Amersham),
and 0.3 .mu.l or 8 U AMV-RT (Stratagene). cDNA synthesis occurred
during the 90 minutes incubation at 42.degree. C. The HIV-1
protease gene was than amplified using the following reaction
mixture: 5 .mu.l cDNA, 4.5 .mu.l 10.times. Taq buffer, 0.3 .mu.l 25
mM dXTPs, 1 .mu.l (10 pmol) of each PCR primer, 38 .mu.l H.sub.2 O,
and 0.2 .mu.l (1 U) Taq. . Alternatively, the Titon One Tube RT-PCR
system (Boehringer Mannheim) was used to perform RT-PCR. Codon
positions involving resistance to saquinavir, ritonavir, indinavir,
nelfinavir and VX-478 have been described (Shinazi et al) and PCR
amplification primers were chosen outside these regions. The primer
design was based on HIV-1 published sequences (mainly genotype B
clade) (Myers et al.) and located in regions that showed a high
degree of nucleotide conservation between the different HIV-1
clades. The final amplified region covered the HIV-1 protease gene
from codon 9 to codon 99. The primers for amplification had the
following sequence: outer sense primer Pr16: 5'
bio-CAGAGCCAACAGCCCCACCAG 3' (SEQ ID NO 1); nested sense primer
Prot2bio: 5' CCT CAR ATC ACT CTT TGG CAA CG 3' (SEQ ED NO 3);
nested antisense primer Prot6bio: 3' TAA TCR GGA TAA CTY TGA CAT
GGT C 5' (SEQ ID NO 4); and outer antisense primer RT12: 5'
bioATCAGGATGGAGTTCATAACCCATCCA 3' (SEQ ID NO 2). Annealing occurred
at 57.degree. C., extension at 72.degree. C. and denaturation at
94.degree. C. Each step of the cycle took 1 minute, the outer PCR
contained 40 cycles, the nested round 35. Nested round PCR products
were analyzed on agarose gel and only clearly visible amplification
products were used in the LiPA procedure. Quantification of viral
RNA was obtained with the HIV Monitor.TM.test (Roche, Brussels,
Belgium). Later on, new sets of primers for amplification were
selected. For the amplification of HIV protease codon 30-84: outer
sense primer prot16: 5'-CAGAGCCAACAGCCCCACCAG-3' (SEQ ID NO 501),
outer antisense primer prot5: 5'-TTTTCTTCTGTCAATGGCCATTGTTT-3' (SEQ
ID NO 502) were used. Annealing occurred at 50.degree. C.,
extension at 68.degree. C. and denaturation at 94.degree. C. for 35
cycles for the outer PCR. For the nested PCR annealing occurred at
45.degree. C., denaturation at 94.degree. C. and extension at
92.degree. C. with primers: nested sense primers prot2a-bio:
5'-bio-CCTCAAATCACTCTTTGGCAACG-3' (SEQ ID NO 503)and prot2b-bio:
5'-bio-CCTCSGSTCSCTCTTTGGCSSCG-3' (SEQ ED NO 504), and nested
antisense primer prot31-bio: 5'-bio-AGTCAACAGATTTCTTTCCAAT-3' (SEQ
ID NO 6). For the amplification of HIV protease codon 90, the outer
PCR was as specified for HIV protease codon 30-84. For the nested
PCR, nested sense primer prot41-bio: 5'-bio-CCTGTCAACATAATTGCAAG-3'
(SEQ ID NO 505) and nested antisense primers prot6a:
5'-bio-CTGGTACAGTTTCAATAGGGCTAAT-3' (SEQ ID NO 506), prot6b:
5'-bio-CTGGTACAGTTTCAATAGGACTAAT-3' (SEQ ID NO 507), prot6c:
5'-bio-CTGGTACAGTCTCAATAGGACTAAT-3' (SEQ ID NO 508), prot6d:
5'-bio-CTGGTACAGTCTCAATAGGGCTAAT-3' (SEQ ID NO 509) were used. For
the nested PCR the annealing temperature occurred at 45.degree. C.
Primers were tested on a plasmid, which contained an HIV fragment
of 1301 bp ligated in a pGEM-T vector. The fragment contains
protease, reverse transcriptase and the primer sites of first and
second round PCR. By restriction with SacI the plasmid is
linearised.
Selected PCR products were cloned into the pretreated EcoRV site of
the pGEMT vector (Promega). Recombinant clones were selected after
.alpha.-complementation and restriction fragment length analysis,
and sequenced using standard sequencing techniques with plasmid
primers and internal HIV protease primers. Sometimes biotinylated
fragments were directly sequenced with a dye-terminator protocol
(Applied Biosystems) using the amplification primers.
Alternatively, nested PCR was carried out with analogs of the
nested primers, in which the biotin group was replaced with the T7-
and SP6-primer sequence, respectively. These amplicons were than
sequenced with an SP6- and T7-dye-primer procedure.
Example 2
Selection of a Reference Panel
Codon positions involving resistance to saquinavir, ritonavir,
indinavir, nelfmiavir and VX-478 have been described (Shiazi et al.
1997). It was the aim to clone in plasmids those viral protease
genes that are covering the different genetic motifs at those
important codon positions conferring resistance against the
described protease inhibitors.
After careful analysis of 312 protease gene sequences, obtained
after direct sequencing of PCR fragments, a selection of 47 PCR
fragments which covered the different target polymorphisms and
mutations were retained and cloned in plasmids using described
cloning techniques. The selection of samples originated from naive
or drug-treated European, Brazilian or US patients. These 47
recombinant plasmids are used as a reference panel, a panel that
was sequenced on both strands, and biotinylated PCR products from
this panel were used to optimize probes for specificity and
sensitivity.
Although this panel of 47 samples is a representative selection of
clones at this moment, it is important to mention here that this
selection is an fact only a temporally picture of the variability
of the virus, and a continuous update of this panel will be
mandatory. This includes on ongoing screening for the new variants
of the virus, and recombinant cloning of these new motifs.
Probe Selection and LiPA Testing
To cover all the different genetic motifs in the reference panel, a
total of 471 probes were designed (codon 30: 40 probes; codon
46/48: 72 probes; codon 50: 55 probes; codon 54: 54 probes, codon
82/84: 130 probes; codon 90: 120 probes). Table 3 shows the
different probes that were selected for the different codon
positions.
It was the aim to adapt all probes to react specifically under the
same hybridization and wash conditions by carefully considering the
% (G+C), the probe length, the final concentration of the buffer
components, and hybridization temperature (Stuyver et al., 1997).
Therefore, probes were provided enzymatically with a poly-T-tail
using the TdT (Pharmacia) in a standard reaction condition, and
purified via precipitation. For a limited number of probes with 3'
T-ending sequences, an additional G was incorporated between the
probe sequence and the poly-T-tail in order to limit the
hybridizing part to the specific probe sequence and to exclude
hybridization with the tail sequence. Probe pellets were dissolved
in standard saline citrate (SSC) buffer and applied as horizontal
parallel lines on a membrane strip. Control lines for amplification
(probe 5' TAGGGGGAATTGGAGGTTTTAG 3 ' (SEQ ID NO: 125), HIV protease
aa 47 to aa 54) and conjugate incubation (biotinylated DNA) were
applied alongside. Probes were immobilized onto membranes by
baking, and the membranes were sliced into 4 mm strips also called
LiPA strips.
Selection of the amplification primers and PCR amplification was as
described in example 1. In order to select specific reacting probes
out of the 471 candidate probes, LiPA tests were performed with
biotinylated PCR fragments from the reference panel. To perform
LiPA tests, equal amounts (10 .mu.l) of biotinylated amplification
products and denaturation mixture (0.4 N NaOH/0.1l% SDS) were
mixed, followed by an incubation at room temperature for 5 minutes.
Following this denaturation step, 2 ml hybridization buffer
(2.times.SSC, 0.1% SDS, 50 mM Tris pH7.5) was added together with a
membrane strip and hybridization was carried out at 39.degree. C.
for 30 min. Then, the hybridization mix was replaced by stringent
washing buffer (same composition as hybridization buffer), and
stringent washing occurred first at room temperature for 5 minutes
and than at 39.degree. C. for another 25 minutes. Buffers were than
replaced to be suitable for the streptavidine alkaline phosphatase
conjugate incubations. After 30 minutes incubation at room
temperature, conjugate was rinsed away and replaced by the
substrate components for alkaline phosphatase,
Nitro-Blue-Tetrazolium and 5-Bromo-4-Chloro-3-Indolyl Phosphate.
After 30 minutes incubation at room temperature, probes where
hybridization occurred became visible because of the purple brown
precipitate at these positions.
After careful analysis of the 471 probes, the most specific and
sensitive probes (n=46) were finally selected, covering the natural
and drug-selected variability in the vicinity of aa 30, 46, 48, 50,
54, 82, 84, and 90. FIG. 2 shows the reactivity of the finally
selected probes with the reference panel.
Example 3
LiPA Testing on Clinical Samples
A total of 856 samples were tested on this selection of 46 specific
probes. The geographical origin of these samples is as follows:
USA:359; France: 154; UK:36; Brazil 58; Spain 35; Belgium 199;
Luxembourg: 15.
From this population, a total of 144 samples were sequenced which
allowed to separate the genotype B samples (94) from the non-B
samples (50). After analysis of these genotyped samples on LiPA,
the genotypic reactivity on the selected probes was scored. FIGS.
4A to 4F show these results for the different codon positions and
for the genotype B versus non-B group. From these tables, it is
clear that there is little difference in sequence usage for the
different codon positions with resect to specific reactivities at
the different probes.
The total collection of 856 samples was then tested on the
available 46 probes. After dissection of those reactivities over
the different probes and different geographical origin, the picture
looks as is presented in FIGS. 5A to 5F. Again here, the majority
of the sequences used at the different codon positions are
restricted to some very abundant wild type motifs. It is important
to mention here that the majority of these samples are taken from
patients never treated with protease inhibitors, en therefore, the
majority of the reactivities are found in wild type motifs.
Nevertheless, it is clear from some codon positions that the
variability at some codon positions in the mutant motif might be
considerable, and again, a continuous update on heavily treated
patients is mandatory. Another issue is the amount of double blank
reactivities, which is in this approach reaching up to 5% in
global; with some peak values for some countries for some codon
positions: for example 13.8% for codon 82/85 in Brazil; and 18.1%
for codon 90 in Belgium.
The continuous update resulted in a further selection of probes.
This later configuration of the strip is indicated in table 7.
REFERENCES
Asseline U, Delarue M, Lancelot G, Toulme F, Thuong N (1984)
Nucleic acid-binding molecules with high affinity and base sequence
specificity: intercalating agents covalently linked to
oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA
81(11):3297-301.
Barany F. Genetic disease detection and DNA amplification using
cloned thermostable ligase. Proc Natl Acad Sci USA 1991; 88:
189-193.
Bej A, Mahbubani M, Miller R, Di Cesare J, Haff L, Atlas R.
Mutiplex PCR amplification and immobilized capture probes for
detection of bacterial pathogens and indicators in water. Mol Cell
Probes 1990; 4:353-365.
Compton J. Nucleic acid sequence-based amplification. Nature 1991;
350: 91-92.
Condra et al. 1995. In vivo emergence of HIV-1 variants resistant
to multiple protease inhibitors. Nature 374: 569-571.
Condra et al. 1995. In vivo emergence of HIV-1 variants resistant
to multiple protease inhibitors. Nature 374: 569-571.
Duck P. Probe amplifier s n based on chimeric cycling
oligonucleotides. Biotechniques 1990; 9: 142-147.
Eberle et al. 1995. Resistance of HIV type 1 to proteinase
inhibitor Ro 31-8959. AIDS Research and Human Retroviruses 11:
671-676.
Emini et al. 1994. Phenotypic and genotypic characterization of
HIV-1 variants selected during treatment with the protease
inhibitor L-735, L-524. Third International Workshop on HIV Drug
Resistance, Kauai, Hi., USA.
Guatelli J, Whitfield K, Kwoh D, Barringer K, Richman D, Gengeras
T. Isothermal, in vitro amplification of nucleic acids by a
multienzyme reaction modeled after retroviral replication. Proc
Natl Acad Sci USA 1990; 87: 1874-1878.
Huff et al. 1991. HIV protease: a novel chemotherapeutic target for
AIDS. J. Med. Chem. 34: 2305-2314.
Hunter et al. 1994. Macromolecular interactions in the assembly of
HIV and other retroviruses. Seminars in Virology 5: 71-83.
Kempf et al. 1994. Pharmacokinetic and in vitro selection studies
with ABT-538, a potent inhibitor of HIV protease with high oral
bioavailability. 34th Interscience Conference on Antimicrobial
Agents and Chemotherapy, Orlando, Fla., USA.
Kohl et al. 1988. Active human immunodeficiency virus protease is
required for viral infectivity. Proc. Natl. Acad. Sci. USA.
85:4686-4690.
Kwok S, Kellogg D, McKinney N, Spasic D, Goda L, Levenson C,
Sinisky. Effects of primer-template mismatches on the polymerase
chain reaction: Human immunodeficiency views type 1 model studies.
Nucl. Acids Res. 1990; 18: 999.
Landgren U, Kaiser R, Sanders J, Hood L. A ligase-mediated gene
detection technique. Science 1988; 241:1077-1080.
Lomeli H, Tyagi S, Printchard C, Lisardi P, Kramer F. Quantitative
assays based on the use of replicatable hybridization probes. Clin
Chem 1989; 35: 1826-1831.
Matsukura M, Shinozuka K, Zon G, Mitsuya H, Reitz M, Cohen J,
Broder S (1987) Phosphorothioate analogs of oligodeoxynucleotides:
inhibitors of replication and cytopathic effects of human
immunodeficiency virus. Proc. Natl. Acad. Sci. USA
84(21):7706-10.
Meek et al. 1989. Proc. Natl. Acad. Sci. USA. 86: 1841-1845.
Miller P, Yano J, Yano E, Carroll C, Jayaram K, Ts'o P (1979)
Nonionic nucleic acid analogues. Synthesis and characterization of
dideoxyribonucleoside methylphosphonates. Biochemistry
18(23):5134-43.
Myers et al. 1996. Human retroviruses and AIDS 1996. Los Alamos
Laboratory, Los Alamos, N.Mex. Navia et al. 1989. Three-dimensional
structure of aspartyl protease from human immunodeficiency virus
HIV-1. Nature 337: 615-620.
Nielsen P, Egholm M, Berg R. Buchardt O (1993) Sequence specific
inhibition of DNA restriction enzyme cleavage by PNA.
Nucleic-Acids-Res. 21(2): 197-200.
Nielsen P, Egholm M, Berg R, Buchardt O (1991) Sequence-selective
recognition of DNA by strand displacement with a
thymine-substituted polyamide. Science 254(5037):1497-500.
Patick et al. 1996. Antiviral and resistance studies of AG1343, an
orally bioavailable inhibitor of human immunodeficiency virus
protease. Antimicrobial Agents and Chemotherapy 40: 292-297; 40:
1575 (erratum).
Peng et al. 1989. Role of human immunodeficiency virus type
1-specific protease in core protein maturation and viral
infectivity. J. Virol. 63: 2550-2556.
Rao et al. 1996. Structural and modeling analysis of the basis of
viral resistance to VX-478. Fifth International Workshop on HIV
Drug Resistance, Whistler, Canada, abstract n.sup.o : 22.
Saiki R, Walsh P, Levenson C, Erlich H. Genetic analysis of
amplified DNA with immobilized sequence-specific oligonucleotide
probes Proc Natl Acad Sci USA 1989; 86:6230-6234.
Schmit et al. 1996. Resistance-related mutations in the HIV-1
protease gene of patients treated for 1 year with the protease
inhibitor ritonavir (ABT-538). AIDS 10: 995-999.
Shinazi et al. 1997. Mutations in retroviral genes associated with
drug resistance. International Antiviral News 5: 129-142.
Stuyver L, Rossau R, Wyseur A, et al. Typing of hepatitis C virus
isolates and characterization of new subtypes using a line probe
assay. J. Gen. Virol. 1993; 74: 1093-1102.
Tisdale et al. 1994. Comprehensive analysis of HIV-1 variants
individually selected for resist to six HIV protease inhibitors.
Third International Workshop on HIV Drug Resistance, Kauai, Hi.,
USA.
Wlodawer et al. 1993. Structure-based inhibitors of HIV-1 protease.
Annu. Rev. Biochem. 62:543-585.
Wlodawer et al. 1989. Science 245: 616-621.
Wu D, Wallace B. The ligation amplification reaction
(LAR)--amplification of specific DNA sequences using sequential
rounds of template-dependent ligation. Genomics 1989;
4:560-569.
TABLE 1 26 27 28 29 30 31 32 33 34 3 Tm lengte Seq ID ACA GGA GCA
GAT GAT ACA GTA TTA GAA GAA pc30w25 GCA GAT GAT ACA GT 40 14 31
pc30w29 A GCG GAT GAT ACA 36 13 35 pc30w32 GCA GAT GAC ACA GT 42 14
38 pc30w36 GCA GAC GAT ACA GG 40 14 42 pc30m23 A GCA GAT AAT ACA GT
40 15 29 44 45 46 47 48 49 50 51 52 CCA AAA ATG ATA GGG GGA ATT GGA
GGT pc48w47 AAA ATG ATA GGG GGA 42 15 93 pc48w45 A ATG ATA GGA GGA
ATT 42 16 91 pc48w72 A AAA ATA ATA GGG GGA 42 16 120 pc48m41 ATG
ATA GTG GGA ATT 40 15 87 48 49 50 51 52 53 54 GGG GGA ATT GGA GGT
TTT ATC pc50w31 GGA ATT GGA GGT TTT 42 15 151 pc50w44 GGA ATT GGG
GGT TTG 42 15 164 pc50w52 GA ATT GGA GGC TTG 14 172 pc50m37 GGG GGA
GTT GGA 40 12 157 51 52 53 54 55 56 57 58 GGA GGT TTT ATC AAA GTA
AGA CAG pc54w3 GT TTT ATC AAA GTA AGA 42 17 178 pc54w34 GA GGT TTT
ATC AAA GT 42 16 212 pc54w14 GGT TTT ATC AAG GTA A 42 16 189
pc54w19 A GGC TTT ATC AAA GTA 42 16 194 pc54w22 GA GGT TTT ATT AAA
GTA 42 17 197 pc54w26 A GGT TTC ATT AAG GTA 42 16 202 pc54w27 GGT
TTT ATT AAG GTA A 40 16 204 pc54m55 A GGT TTT GCC AAA GT 38 15
pc54m35 GGT TTT GTC AAA GTA 40 15 213 pc54m37 GGT TTT GTC AGA GTA
42 15 215 78 79 80 81 82 83 84 85 86 87 GGA CCT ACA CCT GTC AAC ATA
ATT GGA AGA pc82w91 ACA CCT GTC AAC ATA A 44 16 318 pc82w60 CA CCT
GTC AAT ATA ATG 42 17 287 pc82w111 A CCG GTC AAC ATA ATT 44 16 338
pc82w89 ACA CCT GTT AAC ATA AG 42 17 316 pc82w42 CA CCT GTC AAC GTA
42 14 269 pc82m36 ACA CCT ACC AAC ATA 42 15 263 pc82m67 ACA CCT ACC
AAC GT 42 14 294 pc82m38 ACA CCT TTC AAC ATA 40 15 265 pc82m105 ACG
CCC TTC AAC ATA 44 15 332 pc82m127 CA CCT TTC AAC GTA ATG 44 17 354
pc82m40 ACA CCT GCC AAC ATA 44 15 267 pc82m63 CA CCT GCC AAT ATA AG
42 16 290 pc82m101 ACA CCT ATC AAC ATA ATG 44 18 328 86 87 88 89 90
91 92 93 94 GGA AGA AAT CTG TTG ACT CAG ATT GGT pc90w27 AAT CTG TTG
ACT CA 38 14 384 pc90w37 AAT CTG TTG ACT CAG ATG 42 18 394 pc90w39
GA ACT CTG TTG ACT C 44 15 396 pc90w50 AAT ATG TTG ACT CAG 40 15
407 pc90w52 AAT TTG TTG ACT CAG 40 15 409 pc90w69 GA AAC CTG TTG
ACT 40 14 426 pc90w73 TG TTG ACA CAG CTT G 44 15 430 pc90w79 TG TTG
ACC CAG ATT G 44 15 436 pc90m43 A AAT CTG ATG ACT CA 40 15 400
pc90m56 AAT ATG ATG ACC CAG 42 15 413
TABLE 2 Protease Inhibitors Compound Amino Protease acid Inhibitors
change Codon change A-77003 R8Q CGA to CAA R8K CGA to AAA V32I GTA
to ATA M46I ATG to ATA M46L ATG to TTC M46F ATG to TTC M46V ATG to
GTG G48V GGG to GTG A71V GCT to GTT V82I GTC to ATC V82A GTC to GCC
L63P CTC to CCC A71T GCT to ACT A71V GCR to GTT G73S GGT to GCT
V82A GTC to GCC V82F GTC to TTC V82T GTC to ACC I84V ATA to GTA
L90M TTG to ATG P9941 V82A GTC to GCC Ro 31-8959 L10I CTC to ATC
(saquinavir) G48V GGG to GTG I54V ATC to GTC I54V ATA to GTA G73S
GGT to AGT V82A GTC to GCC I84V ATA to GTA L90M TTG to ATG RPI-312
I84V ATA to GTA SC-52151 L24V TTA to GTA G48V GGG to GTG A71V GCT
to GTT V75I GTA to ATA P81T CCT to ACT V82A GTC to GCC N88D AAT to
GAT SC-55389A L10F CTC to CGC N88S AAT to AGT SKF108842 V82T GTC to
ACC I84V ATA to GTA SKF108922 V82A GTC to GCC V82T GTC to ACC VB
11,328 L10F CTC to GGC M46I ATG to ATA I47V ATA to CTA I50V ATT to
GTT 184V ATA to GTA VX-478 L10F CTC to CGC (141W94) M46I ATG to ATA
I47V ATA to CTA I50V ATT to GTT I84V ATA to GTA XM323 L10F CTC to
CGC K45I AAA to ATA M46L ATG to CTG V82A GTC to GCC V82I GTC to ATC
V82F GTC to TTC I84V ATA to GTA L97V TTA to GTA I82T ATC to ACC
A-75925 V32I GTA to ATA ABT-538 K20R AAG to AAA (ritonavir) L33F
TTA to TTC M36I ATG to ATA M46I ATG to ATA I54L ATC to ? I54V ATC
to GTC A71V GTC to GTT V82F GTC to TTC V82A GTC to GCC V82T GTC to
ACC V82S GTC to TCC I84V ATA to GTA L90M TTG to ATG AG1343 D30N GAT
to AAT (nelfinavir) M36I M46I ATG to ATA L63P CTC to CCC A71V GCT
to GTT V771 184V ATA to GTA N88D L90M TTG to ATG BILA 1906 V32I GTA
to ATA BS M46I ATG to ATA M46L ATG to TTG A71V GCT to CTT I84A ATA
to GCA 184V ATA to GTA BILA 2011 V32I GTA to ATA (palinavir) A71V
GCT to GTT I84A ATG to ATA L63P CTC to CCC BILA 2185 BS L23I CTA to
ATA BMS 186,318 A71T GCT to ACT V82A GTC to GCC DMP450 L10F CTC to
TTC M46I ATG to ATA D60E GAT to GAA I84V ATA to GTA KNI-272 V32I
GTA to ATA MK-639 L10I CTC to ATC (L-735, 524, L10R CTC to CGC
indinavir) L10V CTC to GTC K20M AAG to ATG K20R AAG to AAA L24I TTA
to ATA V32I GTA to ATA M46I ATG to ATA M46L ATG to TTG I54V ATC to
GTC
TABLE 3 26 27 28 29 30 31 32 33 34 35 length Seq ID ACA GGA GCA GAT
GAT ACA GTA TTA GAA GAA P30w1 A GCA GAT GAT ACA GTA TT 18 7 P30w2
GA GCA GAT GAT ACA GTA TT 19 8 P30w3 A GCA GAT GAT ACA GTA TTA 19 9
P30w4 GGA GCA GAT GAT ACA GTA TT 20 10 P30w5 GGA GCA GAT GAT ACA
GTA TTA 21 11 P30w6 ACA GGA GCA GAT GAT ACA 18 12 P30w7 CA GGA GCA
GAT GAT ACA GT 19 13 P30w8 A GGA GCA GAT GAT ACA GTA TG 20 14 P30w9
GGA GCA GAT GAT ACA GTA TG 19 15 P30w10 ACA GGA GCA GAT GAT ACA GG
19 16 P30m11 A GCA GAT AAT ACA GTA TT 18 17 P30m12 GA GCA GAT AAT
ACA GTA TT 19 18 P30m13 A GCA GAT AAT ACA GTA TTA 19 19 P30m14 GGA
GCA GAT AAT ACA GTA TT 20 20 P30m15 GGA GCA GAT AAT ACA GTA TTA 21
21 P30m15 ACA GGA GCA GAT AAT ACA 18 22 P30m17 CA GGA GCA GAT AAT
ACA GT 19 23 P30m18 A GGA GCA GAT AAT ACA GTA TG 20 24 P30m19 GGA
GCA GAT AAT ACA GTA TG 19 25 P30m20 ACA GGA GCA GAT AAT ACA GG 19
26 p30w21 A GCA GAT GAT ACA GT 15 27 p30w22 A GCA GAT GAT ACA GTA G
16 28 p30m23 A GCA GAT AAT ACA GTA 15 29 p30m24 A GCA GAT AAT ACA
GTA G 16 30 p30w25 GCA GAT GAT ACA GT 14 31 p30w26 A GCA GAT GAT
ACA GG 14 32 p30w27 CA GAT GAT ACA GT 13 33 p30w28 GA GCG GAT GAT
ACA 14 34 p30w29 A GCG GAT GAT ACA 13 35 p30m30 GCA GAT AAT ACA GTA
15 36 p30m31 GCA GAT AAT ACA GT 14 37 p30w32 GCA GAT GAC ACA GT 14
38 p30w33 CA GAT GAC ACA GTA G 14 39 p30w34 CA GAT GAT ACA ATA TT
16 40 p30w35 GCA GAT GAT ACA ATA TG 16 41 p30w36 GCA GAC GAT ACA GG
13 42 p30w37 GCA GAC GAT ACA GT 14 43 p30w38 A GAT GAT ACA ATA TT
15 44 p30w39 A GAT GAT ACA ATA TTA 16 45 p30w40 GCA GAT GAT ACA ATA
15 46 44 45 46 47 48 49 50 51 52 53 54 length Seq ID CCA AAA ATG
ATA GGG GGA ATT GGA GGT TTT ATC P48w1 GTA GGG GGA ATT GGA GGT GG 18
47 P48w2 GTA GGG GGA ATT GGA GGT TG 19 48 P48w3 GTA GGG GGA ATT GGA
GGT TTG 20 49 P48w4 GTA GGG GGA ATT GGA GGT TTT 21 50 P48w5 G GTA
GGG GGA ATT GGA GGT TTG 21 51 P48w6 ATG GTA GGG GGA ATT GGA 18 52
P48w7 ATG GTA GGG GGA ATT GGA G 19 53 P48w8 A ATG GTA GGG GGA ATT
GGA 19 54 P48w9 A ATG GTA GGG GGA ATT GGA G 20 55 P48w10 A ATG GTA
GGG GGA ATT GGA GGG GG 22 56 P48w21 ATA ATA GGG GGA ATT GGA 18 57
P48w22 ATG ATA GGG GGA ATT GGA 18 58 P48w23 A ATA ATA GGG GGA ATT
GGA 19 59 P48w24 A ATG ATA GGG GGA ATT GGA 19 60 P48w25 ATA GGG GGA
ATT GGA GGT GG 18 61 P48w26 ATA GGG GGA ATT GGA GGT TG 19 62 P48w28
ATA GGG GGA ATT GGA GGT TTG 20 63 P48w29 ATA GGG GGA ATT GGA GGT
TTT 21 64 P48m11 GTA GTG GGA ATT GGA GGT GG 18 65 P48m12 GTA GTG
GGA ATT GGA GGT TG 19 66 P48m13 GTA GTG GGA ATT GGA GGT TTG 20 67
P48m14 GTA GTG GGA ATT GGA GGT TTT 21 68 P48m15 G GTA GTG GGA ATT
GGA GGT TTG 21 69 P48m16 ATG GTA GTG GGA ATT GGA 18 70 P48m17 ATG
GTA GTG GGA ATT GGA G 19 71 P48m18 A ATG GTA GTG GGA ATT GGA 19 72
P48m19 A ATG GTA GTG GGA ATT GGA G 20 73 P48m20 A ATG GTA GTG GGA
ATT GGA GGG GG 22 74 P48m29 ATA GTG GGA ATT GGA GGT GG 18 75 P48m30
ATA GTG GGA ATT GGA GGT TG 19 76 P48m31 ATG ATA GTG GGA ATT GGA 18
77 P48m32 ATG ATA GTG GGA ATT GGA G 19 78 P48m33 A ATG ATA GTG GGA
ATT GGA 19 79 p48w34 G ATA GGG GGA ATT G 14 80 p48w35 TG ATA GGG
GGA ATT G 15 81 p48w36 TG ATA GGG GGA ATT GG 16 82 p48w37 ATG ATA
GGG GGA ATT 15 83 p48m38 G ATA GTG GGA ATT G 14 84 p48m39 TG ATA
GTG GGA ATT G 15 85 p48m40 TG ATA GTG GGA ATT GG 16 86 p48m41 ATG
ATA GTG GGA ATT 15 87 p48w42 ATA ATA GGG GGA ATT 15 88 p48w43 TG
ATA GGG GGA GTT 14 89 p48w44 G ATA GGG GGA GTT G 14 90 p48w45 A ATG
ATA GGA GGA ATT 16 91 p48w46 ATG ATA GGG GGA ATT 15 92 p48w47 AAA
ATG ATA GGG GGA 15 93 p48w48 A AAA ATG ATA GGG GG 15 94 p48w49 AA
ATG ATA GGG GGA AG 15 95 p48w50 AAA ATA ATA GGG GGA AG 16 96 p48w51
AAA ATA AAA AT 15 97 p48m52 AAA ATG ATA GTG GGA AG 16 98 p48w52b
AAA TTG ATA GGG GG 14 99 p48m53 AAA ATG ATA GTG GGA 15 100 p48w53b
AAA TTG ATA GGG GGA 15 101 p48w54 CA AAA TTG ATA G 15 102 p48w55
ATG GTA GGG GGA ATT 15 103 p48w56 AA ATG GTA GGG GGA 14 104 p48w57
A AAA ATG GTA GGG G 14 105 p48w58 ATG ATA GGG GAA ATT 15 106 p48w59
ATA GGG GAA ATT GGA 15 107 p48w60 ATA GGG GAA ATT GGA G 16 108
p48w61 ATG ATA GGG GGG ATT 15 109 p48w62 ATA GGG GGG ATT GG 14 110
p48w63 A GGG GGG ATT GGA 13 111 p48m64 AAA ATA ATA GTG GGA 15 112
p48m65 A AAA ATA ATA GTG GGA 16 113 p48m66 CA AAA ATA ATA GTG GG 16
114 p48m67 AAA TTG ATA GTG GGA 15 115 p48m68 A AAA TTG ATA GTG GGA
16 116 p48m69 CA AAA TTG ATA GTG G 15 117 p48w70 AAA ATG ATA GGG GG
14 118 p48w71 A AAA ATG ATA GGG G 14 119 pc48w72 A AAA ATA ATA GGG
GGA 16 120 45 46 47 48 49 50 51 52 53 54 length Seq ID AAA ATG GTA
GGG GGA ATT GGA GGT TTT ATC P50w1 GGG GGA ATT GGA GGT TTT 18 121
P50w2 A GGG GGA ATT GGA GGT TTT 19 122 P50w3 TA GGG GGA ATT GGA GGT
TTT 20 123 P50w4 A GGG GGA ATT GGA GGT TTT AG 20 124 P50w5 TA GGG
GGA ATT GGA GGT TTT AG 21 125 P50w6 GTA GGG GGA ATT GGA GGT TGG 19
126 P50w7 G GTA GGG GGA ATT GGA GGT TGG 20 127 P50w8 GTA GGG GGA
ATT GGA GGT TTG 20 128 P50w9 GTA GGG GGA ATT GGA GGT TTT 20 129
P50w10 TG GTA GGG GGA ATT GGA GGT GG 20 130 p50w21 GG GGA ATT GGA
GGT TTT 17 131 P50w22 GG GGA ATT GGA GGT TTG 16 132 P50w23 GG GGA
ATT GGA GGT TTT AG 18 133 P50w24 GG GGA ATT GGA GGT TG 15 134
P50w25 G GGA ATT GGA GGT TTT AT 18 135 P50w26 GG GGA ATT GGA GGT
TTT 17 136 P50m11 GGG GGA GTT GGA GGT TTT 18 137 P50m12 A GGG GGA
GTT GGA GGT TTT 19 138 P50m13 TA GGG GGA GTT GGA GGT TTT 20 139
P50m14 A GGG GGA GTT GGA GGT TTT AG 20 140 P50m15 TA GGG GGA GTT
GGA GGT TTT AG 21 141 P50m16 GTA GGG GGA GTT GGA GGT TGG 19 142
P50m17 G GTA GGG GGA GTT GGA GGT TGG 20 143 P50m18 GTA GGG GGA GTT
GGA GGT TTG 20 144 P50m19 GTA GGG GGA GTT GGA GGT TTT ATC 21 145
P50m20 TG GTA GGG GGA GTT GGA GGT GG 20 146 P50m27 GG GGA GTT GGA
GGT TTG 19 147 P50m28 GG GGA GTT GGA GGT TTT AG 18 148 P50m29 GG
GGA GTT GGA GGT TG 15 149 P50m30 G GGA GTT GGA GGT TTT AT 18 150
p50w31 GGA ATT GGA GGT TTT 15 151 p50w32 G GGA ATT GGA GGT TGG 15
152 p50m33 GGA GTT GGA GGT TTT 15 153 p50m34 G GGA GTT GGA GGT TGG
14 154 p50m35 GGG GGA GTT GGA G 13 155 p50m36 GG GGA GTT GGA G 12
156 p50m37 GGG GGA GTT GGA 12 157 p50w38 GGA ATT GGG GGT TTG 14 158
p50w39 GA ATT GGG GGT TTT 14 159 p50w40 GA ATT GGG GGT TTT AG 15
160 p50w41 GGA ATT GGG GGT TG 13 161 p50w42 GGA ATT GGG GGT G 12
162 p50w43 GA ATT GGG GGT TG 12 163 p50w44 GA ATT GGG GGT TTG 13
164 p50w45 GGG GGA ATT GCA G 13 165 p50w46 GGA ATT GCA GGT TG 14
166 p50w47 GGA ATT GCA GGT G 13 167 p50w48 GGA ATT GGA GGG TTG 14
168 p50w49 GA ATT GGA GGG TTG 13 169 p50w50 GA ATT GGA GGG TTT 14
170 p50w51 GGA ATT GGA GGC TTG 14 171 p50w52 GA ATT GGA GGC TTG 13
172 p50w53 GA ATT GGA GGC TTT 14 173 p50m54 GGA GTT GGA GGT TTG 15
174 p50m55 GA GTT GGA GGT TTT 14 175 51 52 53 54 55 56 57 58 length
Seq ID GGA GGT TTT ATC AAA GTA AGA CAG p54w1 GGT TTT ATC AAA GTA A
16 176 p54w2 GT TTT ATC AAA GTA AG 16 177 p54w3 GT TTT ATC AAA GTA
AGA 17 178 p54w4 T TTT ATC AAA GTA AGA 16 179 p54w5 GGT TTT ATC AAA
GTA 15 180 p54w6 GT TTT ATC AAA GTA 15 181 p54m7 GGT TTT GCC AAA
GTA 15 182 p54m8 GT TTT GCC AAA GTA A 15 183 p54m9 GT TTT GCC AAA
GTA AG 16 184 p54m10 T TTT GCC AAA GTA AGA 16 185 p54m11 GGT TTT
GCC AAA GT 14 186 p54m12 GT TTT GCC AAA GTA 14 187 p54w13 GT TTT
ATC AAG GTA AA 16 188 p54w14 GGT TTT ATC AAG GTA A 16 189 p54w15 A
GGT TTT ATC AAG GTA 16 190 p54w16 GT TTT ATC AAA GTC AGA 17 191
p54w17 TTT ATC AAA GTC AGA C 16 192 p54w18 A GGC TTT ATC AAA GTA A
17 193 p54w19 A GGC TTT ATC AAA GTA 16 194 p54m20 A GGT TTT ATT AAA
GTA A 17 195 p54m21 GGT TTT ATT AAA GTA AG 17 196 p54w22 GA GGT TTT
ATT AAA GTA 17 197 p54m22 GA GGT TTT ATT AAA GTA 17 198 p54m23 GGT
TTT ATT GGT TTT AT 16 199 p54m24 GGT TTC ATT AAG GTA 15 200 p54m25
GGT TTC ATT AAG GTA A 16 201 p54w26 A GGT TTC ATT AAG GTA 16 202
p54m26 A GGT TTC ATT AAG GTA 16 203 p54w27 GGT TTT ATT AAG GTA A 16
204 p54m27 GGT TTT ATT AAG GTA A 16 205 p54m28 A GGT TTT ATT AAG
GTA 16 206 p54m29 GA GGT TTT ATT AAG GT 16 207 p54m30 GGT TTT ATT
AAG GTA AG 17 208 p54w31 GGT TTT ATC AAA GTA A 16 209 p54w32 A GGT
TTT ATC AAA GTA A 17 210 p54w33 A GGT TTT ATC AAA GTA 16 211 p54w34
GA GGT TTT ATC AAA GT 16 212 p54m35 GGT TTT GTC AAA GTA 15 213
p54m36 GGT TTT GTC AAA GTA A 16 214 p54m37 GGT TTT GTC AGA GTA 15
215 p54m38 GGT TTT GTC AGA GTA A 16 216 p54w39 GGG TTT ATC AAA GTA
15 217 p54w40 GGG TTT ATC AAA GTA A 16 218 p54w41 GGC TTC ATC AAA
GT 14 219 p54w42 GA GGC TTC ATC AAA 14 220 p54m48 GGT TTT GTC AAA
GT 14 221 p54m49 GT TTT GTC AGA GTA 14 222 p54m50 GGT TTT GTC AGA
GT 14 223 p54w51 A GGT TTA ATC AAA GTA 16 224 p54w52 GA GGT TTA ATC
AAA GT 16 225 p54m53 GGT TTT ACC AAA GTA 15 226 p54m54 GGT TTT ACC
AAA GT 14 227 78 79 80 81 82 83 84 85 86 87 length Seq ID GGA CCT
ACA CCT GTC AAC ATA ATT GGA AGA P82w1 CCT ACA CCT GTC AAC ATA AG 19
228 P82w2 CCT ACA CCT GTC AAC ATA ATG 20 229 P82w3 CCT ACA CCT GTC
AAC ATA ATT 21 230 P82w4 A CCT ACA CCT GTC AAC ATA AG 20 231 P82w5
A CCT ACA CCT GTC AAC ATA ATG 21 232 P82w6 A CCT ACA CCT GTC AAC
ATA 19 233 P82w7 GA CCT ACA CCT GTC AAC ATA 20 234 P82w8 CA CCT GTC
AAC ATA ATT GGA 20 235 P82w9 A CCT GTC AAC ATA ATT GGA A 20 236
P82w10 ACA CCT GTC AAC ATA ATT GG 20 237 P82W21 A CCT GTC AAC ATA
ATT GGA 19 238 P82m11 CCT ACA CCT ACC AAC ATA AG 19 239 P82m12 CCT
ACA CCT ACC AAC ATA ATG 20 240 P82m13 CCT ACA CCT ACC AAC ATA ATT
21 241
P82m14 A CCT ACA CCT ACC AAC ATA AG 20 242 P82m15 A CCT ACA CCT ACC
AAC ATA ATG 21 243 P82m16 A CCT ACA CCT ACC AAC ATA 19 244 P82m17
GA CCT ACA CCT ACC AAC ATA 20 245 P82m18 CA CCT ACC AAC ATA ATT GGA
20 246 P82m19 A CCT ACC AAC ATA ATT GGA A 20 247 P82m20 ACA CCT ACC
AAC ATA ATT G 19 248 P82m22 CCT ACA CCT TTC AAC ATA ATT 21 249
P82m23 CCT ACA CCT GCC AAC ATA ATT 21 250 P82m24 CCT ACA CCT TCC
AAC ATA ATT 21 251 P82m25 A CCT TTC AAC ATA ATT GGA A 20 252 P82m26
A CCT GCC AAC ATA ATT GGA A 20 253 P82m27 A CCT TTC AAC ATA ATT GGA
A 20 254 P82m28 A CCT ACC AAC ATA ATT 16 255 P82m29 A CCT TTC AAC
ATA ATT GGA 19 256 P82m30 A CCT GCC AAC ATA ATT GGA 19 257 P82m31 A
CCT TCC AAC ATA ATT GGA 19 258 P82w32 T ACA CCT GTC AAC AT 15 259
P82w33 T ACA CCT GTC AAC ATA 16 260 P82w34 ACA CCT GTC AAC ATA 15
261 P82w35 CA CCT GTC AAC ATA 14 262 P82m36 ACA CCT ACC AAC ATA 15
263 P82m37 CA CCT ACC AAC ATA 14 264 P82m38 ACA CCT TTC AAC ATA 15
265 P82m39 CA CCT TTC AAC ATA 14 266 P82m40 ACA CCT GCC AAC ATA 15
267 P82m41 CA CCT GCC AAC ATA 14 268 P82w42 CA CCT GTC AAC GTA 14
269 P82w43 CA CCT GTC AAC GT 13 270 P82w44 CCT ACA CCT GTC AAC 15
271 P82w45 T ACG CCT GTC AAC AT 15 272 P82w46 CT ACG CCT GTC AAC AG
15 273 P82m47 ACA CCT TCC AAC ATA 15 274 P82m48 CA CCT TCC AAC ATA
14 275 P82m49 ACA CCT TCC AAC AT 14 276 P82m50 ACA CCT ATC AAC ATA
15 277 P82m51 CA CCT ATC AAC ATA AG 15 278 P82m52 CA CCT ATC AAC
ATA ATG 16 279 P82m53 A CCT ATC AAC ATA ATG 15 280 P82w54 CCT GTC
AAC ATA ATT 15 281 P82w55 CCT GTT AAC ATA ATT G 16 282 P82w56 A CCT
GTT AAC ATA ATG 15 283 P82w57 CCG GTC AAC ATA ATT 15 284 P82w58 ACG
CCT GTC AAC AT 14 285 P82w59 CCT GTC AAT ATA ATT 15 286 P82w60 CA
CCT GTC AAT ATA ATG 16 287 P82w61 ACA CCT GTC AAT ATA AG 16 288
P82m62 CCT GCC AAT ATA ATT 15 289 P82m63 CA CCT GCC AAT ATA AG 15
290 P82m64 CCT ACC AAC GTA ATT 15 291 P82m65 CCT ACC AAC GTA ATG 14
292 P82m66 CA CCT ACC AAC GTA 14 293 P82m67 ACA CCT ACC AAC GT 14
294 P82m68 CCT TTC AAC GTA ATT 15 295 P82m69 CA CCT TTC AAC GTA AG
15 296 P82m70 ACA CCT TTC AAC GTA 15 297 P82m71 A CCT TTC AAC GTA
ATG 15 298 p82w72 CT GTC AAT ATA ATT G 15 299 p82w73 CCT GTC AAT
ATA ATT G 16 300 p82w74 A CCT GTC AAT ATA ATT 16 301 p82w75 CT GTC
AAT ATA ATT GG 16 302 p82w76 CCT ACG CCT GTC AA 14 303 p82w77 CT
ACG CCT GTC AAC 14 304 p82w78 A CCT ACG CCT GTC AA 15 305 p82w79 A
CCT ACG CCT GTC A 14 306 p82w80 T ACA CCG GTC AAC A 14 307 p82w81
CT ACA CCG GTC AA 13 308 p82w82 CCT ACA CCG GTC A 13 309 p82w83 CA
CCT GTC AAC ATA A 15 310 p82w84 A CCT GTC AAC ATA AT 15 311 p82w85
CT ACA CCT GTC AAC A 15 312 p82w86 ACA CCT GTC AAC AT 14 313 p82w87
A CCT GTT AAC ATA ATT G 17 314 p82w88 CA CCT GTT AAC ATA AG 15 315
p82w89 ACA CCT GTT AAC ATA AG 16 316 p82w90 TCA CCT GTC AAC ATA 14
317 p82w91 ACA CCT GTC AAC ATA A 16 318 p82w92 CA CCT GTC AAC ATA
AT 16 319 p82w93 CCT GTC AAC ATA ATT 15 320 p82w94 A CCT GTC AAC
ATA ATT 16 321 p82w95 CCT GTC AAC ATA ATT G 16 322 p82w96 CCT ACA
CCT GTC AA 14 323 p82w97 T GTC AAC ATA ATT GG 15 324 p82w98 T GTC
AAC ATA ATT GGA 16 325 p82m99 ACA CCT TTC AAC ATA A 16 326 p82m100
T ACA CCT TTC AAC ATA 16 327 p82m101 ACA CCT ATC AAC ATA ATG 17 328
p82m102 ACA CCT ATC AAC ATA AG 16 329 p82m103 CA CCT GCC AAT ATA
ATG 16 330 p82m104 ACA CCT GCC AAT ATA AG 16 331 p82m105 ACG CCC
TTC AAC ATA 15 332 p82m106 CG CCC TTC AAC ATA AG 15 333 p82m107 T
ACG CCC TTC AAC AT 15 334 p82w108 CT ACA CCG GTC AAC 14 335 p82w109
CCT ACA CCG GTC AA 14 336 p82w110 A CCG GTC AAC ATA ATG 15 337
p82w111 A CCG GTC AAC ATA ATT 16 338 p82w112 CT ACA CCA GTC AAC 14
339 p82w113 CT ACA CCA GTC AAC A 15 340 p82w114 ACA CCA GTC AAC ATA
15 341 p82w115 ACA CCA GTC AAC ATA AG 16 342 p82w116 T ACG CCT GTC
AAC AT 15 343 p82w117 ACG CCT GTC AAC ATA 15 344 p82w118 T ACG CCT
GTC AAC A 14 345 p82m119 CCT ACA CCT TTC AAC 15 346 p82m120 CT ACA
CCT TTC AAC 14 347 p82m121 A CCT ACA CCT TTC AA 15 348 p82w122 ACG
CCT GTC AAC ATA AGG 16 349 p82w123 T ACG CCT GTC AAC ATA 16 350
p82w124 CG CCT GTC AAC ATA AGG 15 351 p82m125 T ACA CCT TTC AAC GTA
16 352 p82m126 ACA CCT TTC AAC GTA AGG 16 353 p82m127 CA CCT TTC
AAC GTA ATG 16 354 p82m128 A CCT TTC AAC GTA ATT 16 355 p82o129 C
AAC GTA ATT GGA AGA 16 356 p82o130 C AAC GTA ATT GGA AG 15 357 86
87 88 89 90 91 92 93 94 length Seq ID GGA AGA AAT CTG TTG ACT CAG
ATT GGT P90w1 A AAT CTG TTG ACT CAG 16 358 P90w2 GA AAT CTG TTG ACT
CAG 17 359 P90w3 GA AAT CTG TTG ACT CAG AGG 18 360 P90w4 A AAT CTG
TTG ACT CAG AGG 17 361 P90w5 AGA AAT CTG TTG ACT CAG AGG 19 362
P90w6 AGA AAT CTG TTG ACT CAG ATG 20 363 P90w7 AGA AAT CTG TTG ACT
CAG ATT 21 364 P90w8 AGA AAT CTG TTG ACT CAG ATT GG 20 365 P90w9 GA
AGA AAT CTG TTG ACT CAG AGG 21 366 P90w10 A AGA AAT CTG TTG ACT CAG
ATG 21 367 P90m11 AGA AAT CTG ATG ACT CAG ATG 20 368 P90m12 AGA AAT
CTG ATG ACT CAG ATT 21 369 P90m13 A AGA AAT CTG ATG ACT CAG AGG 20
370 P90m14 GA AGA AAT CTG ATG ACT CAG AGG 21 371 P90m15 A AGA AAT
CTG ATG ACT CAG ATG 21 372 P90m16 GA AGA AAT CTG ATG ACT CAG ATT 20
373 P90m17 GGA AGA AAT CTG ATG ACT CAG 21 374 P90m18 A AGA AAT CTG
ATG ACT CAG 19 375 P90m19 A AAT CTG ATG ACT CAG ATT GG 21 376
P90m20 A AAT CTG ATG ACT CAG ATT G 20 377 P90m21 A AAT CTG ATG ACT
CAG CTT G 20 378 P90m22 A AAT CTG ATG ACT CAG CTT 19 379 P90m23 AAT
CTG ATG ACT CAG CTT G 18 380 P90w24 A AAT CTG TTG ACT CAG CTT G 20
381 P90w25 A AAT CTG TTG ACT CAG CTT 19 382 P90w26 AAT CTG TTG ACT
CAG CTT G 19 383 P90w27 AAT CTG TTG ACT CA 14 384 P90w28 AAT CTG
TTG ACT CAG 15 385 P90w29 A AAT CTG TTG ACT CA 15 386 P90w30 A AAT
CTG TTG ACT CAG 16 387 P90m31 AAT CTG ATG ACT CA 14 388 P90m32 AAT
CTG ATG ACT CAG 15 389 P90m33 A AAT CTG ATG ACT CA 15 390 P90m34 A
AAT CTG ATG ACT CAG 16 391 P90w35 GA AAT CTG TTG ACT C 15 392
P90w36 GA ACT CTG TTG ACT C 15 393 P90w37 T CTG TTG ACT CAG ATG 15
394 P90w38 GA AAT CTG TTG ACT C 15 395 P90w39 GA ACT CTG TTG ACT C
15 396 P90w40 A AAT CTG TTG ACT CA 15 397 P90w41 AAT CTG TTG ACT
CAG 15 398 P90m42 AAT CTG ATG ACT CAG 15 399 P90m43 A AAT CTG ATG
ACT CA 15 400 P90w44 AT CTG TTG ACT CAG AG 15 401 P90w45 CTG TTG
ACT CAG ATT 15 402 P90w46 AGA AAT CTG TTG ACT 15 403 P90m47 AT CTG
ATG ACT CAG AG 15 404 P90m48 CTG ATG ACT CAG ATT 15 405 P90m49 AGA
AAT CTG ATG ACT CA 17 406 P90w50 AAT ATG TTG ACT CAG 15 407 P90w51
GA AAT ATG TTG ACT CA 16 408 P90w52 AAT TTG TTG ACT CAG 15 409
P90w53 GA AAT TTG TTG ACT CA 16 410 P90w54 AAT ATG TTG ACC CAG 15
411 P90w55 A AAT ATG TTG ACC CA 15 412 P90m56 AAT ATG ATG ACC CAG
15 413 P90m57 A CAG ATG ATG ACC CA 15 414 P90w58 AAC ATG TTG ACT
CAG 15 415 P90w59 A AAC ATG TTG ACT CAG 15 416 P90w60 TG TTG ACT
CAG CTT 14 417 P90w61 CTG TTG ACT CAG CTG 14 418 P90m62 CT ATG ACT
CAG CTT 14 419 P90m63 CTG ATG ACT CAG C-G 14 420 P90w64 TG ACT ACA
CAG CTT 14 421 P90w65 CTG TTG ACA CAG C-G 14 422 P90w66 AAT CTG TTG
ACA CAG 15 423 P90w67 AAC CTG TTG ACT CA 13 424 P90w68 A AAC CTG
TTG ACT C 13 425 P90w69 GA AAC CTG TTG ACT 13 426 p90w70 TG TTG ACT
CAG ATT G 15 427 p90w71 TG TTG ACT CAG ATT GGG 16 428 p90w72 G TTG
ACT CAG ATT GGG 15 429 p90w73 TG TTG ACA CAG CTT G 15 430 p90w74
CTG TTG ACA CAG CTT 15 431 p90w75 G TTG ACA CAG CTT GGG 15 432
p90w76 TG TTG ACT CAG CTT G 15 433 p90w77 G TTG ACT CAG ATG 15 434
p90w78 G TTG ACT CAG CTT G 14 435 p90w79 TG TTG ACC CAG ATT G 15
436 p90w80 G TTG ACC CAG ATT G 14 437 p90w81 G TTG ACC CAG ATT GGG
15 438 p90m82 TG ATG ACT CAG ATT G 15 439 p90m83 TG ATG ACT CAG ATT
GGG 16 440 p90m84 G ATG ACT CAG ATT GGG 15 441 p90m85 G ATG ACT CAG
ATT GGT 16 442 p90m86 CTG ATG ACT CAG CTT 15 443 p90m87 TG ATG ACT
CAG CTT G 15 444 P90w88 A AAT CTG TTG ACT CA 15 445 P90w89 A AAT
CTG TTG ACT CA 15 446 p90w90 A AAT CTG TTG ACT CA 15 447 p90w100
AAT CTG ATG ACT CAG 15 448 p90m92 A AAT CTG ATG ACT CA 16 449
p90m93 GA AAT CTG ATG ACT C 15 450 p90m94 CTG ATG ACT CAG ATG 15
451 p90m95 AGA AAT ATG ATG 15 452 p90m96 A AGA AAT ATG ATG ACT 16
453 p90m97 A AGA AAT CTG ATG ACT 16 454 p90m98 A AGA AAT ATA ATG
ACT 16 455 p90m99 A AAT ATA ATG ACT CAG 16 456 p90m100 AAT ATG ATG
ACC CAG 15 457 p90m101 AAC CTG ATG ACT CAG 15 458 p90m102 AGA AAT
TTG ATG ACT C 16 459 p90m103 A AAT TTG ATG ACT ATG ACT 16 460
p90m104 AC CTG ATG ACT CAG 14 461 p90m105 AAT CTG ATG ACT CAG A 16
462 p90m106 AT CTG ATG ACT CAG ATG 16 463 p90m107 AT CTG ATG ACT
CAG 14 464 p90m108 CTG ATG ACT CAG ATT G 16 465 p90m109 AGA AAT CTG
ATG ACT C 16 466 p90m110 AGA AAT CTG ATG ACT 15 467 p90m111 GA AGA
AAT CTG ATG A 15 468 p90m112 GGA AGA AAT CTG ATG A 16 469 p90m113
GA AGA AAT CTG ATG AC 16 470 p90m114 AGA AAT CTG ATG AC 14 471
p90w115 AAT CTG TTA ACT CAG 15 472 p90w116 T CTG TTA ACT CAG ATT 16
473 p90w117 AT CTG TTA ACT CAG AG 15 474 p90w118 AGA AAT TTG TTG
ACT 16 475 p90w119 GA AAT TTG TTG ACT C 15 476 p90w120 AAT TTG TTG
ACT CAG 15 477
TABLE 4 Polymorphic nucleotide sequences. 51 52 53 54 55 56 57 58
codon position gga ggt ttt atc aaa gta aga cag consensus sequence
GGA GGT TTT ATC AAA GTC AGA CAA SEQ ID NO 478 GGA GGT TTC ATT AAG
GTA AAA CAG SEQ ID NO 479 GGA GGT TTT ATT AAG GTA AGA CAG SEQ ID NO
480 GGA GGT TTT ATT AAA GTA AGA CAA SEQ ID NO 481 GGA GGC TTT ATC
AAA GTA AGA CAA SEQ ID NO 482 GGA GGT TTT ATC AAA GTC AGA CAA SEQ
ID NO 483 78 79 80 81 82 83 84 85 codon position gga cct aca cct
gtc aac ata att gg consensus sequence GGA CCT ACA CCG GTC AAC ATA
ATT GG SEQ ID NO 484 GGA CCT ACA CCT GCC AAT ATA ATT GG SEQ ID NO
485 GGA CCT ACG CCC TTC AAC ATA ATT GG SEQ ID NO 486 GGA CCG ACA
CCT GTC ACC ATA ATT GG SEQ ID NO 487 GGA CCT ATA CCT GTC AAC ATA
ATT GG SEQ ID NO 488 87 88 89 90 91 92 93 94 codon position a aga
aat ctg ttg act cag att ggc consensus sequence A AAA AAT CTG ATG
ACT CAG ATT GGC SEQ ID NO 489 A AGA ACT CTG TTG ACT CAG CTT GGA SEQ
ID NO 490 A AGA AAT ATG ATG ACC CAG CTT GGC SEQ ID NO 491 A AGA AAT
ATA ATG ACT CAG CTT GGA SEQ ID NO 492 A AGA AAT CTG CTG ACT CAG ATT
GGG SEQ ID NO 493 A AGA AAT CTG TTG ACA CAG CTT GGC SEQ ID NO 494 A
AGA AAT ATG TTG ACT CAG CTT GGT SEQ ID NO 495 A AGA AAT TTG TTG ACT
CAG ATT GGG SEQ ID NO 496 A AGA AAT ATG TTG ACT CAG CTT GGT SEQ ID
NO 497 A AGA AAT ATG TTG ACT CAG CTT GGA SEQ ID NO 498 A AGA AAT
CTG TTG ACT CAG CTT GGA SEQ ID NO 499 A AGA AAC CTG TTG ACT CAA CTT
GGT SEQ ID NO 500
TABLE 5 probes for probes for probes for codon p30 Type B non-B
codon p48 Type B non-B codon p50 Type B non-B w25 95.7 98 w47 71.3
70 w31 95.7 98 w29 1.1 0 w45 11.7 22 w44 1.1 2 w32 1.1 1 w72 16 4
w52 8.5 4 w36 1.1 0 m41 3.2 0 m37 1.1 6 m23 1.1 0 neg. 0 8 neg. 1.1
0 neg. 0 1 probes for probes for probes for codon p54 Type B non-B
codon p82/84 Type B non-B codon p90 Type B non-B w3 71.3 48 w91
81.9 70 w27 50 2.5 w34 81.9 62 w60 2.1 12 w37 66.1 17.5 w14 3.2 18
w111 1.1 0 w39 7.1 0 w19 6.4 0 w89 1.1 10 w50 12.5 65 w22 4.3 8 w42
4.3 2 w52 7.1 2.5 w26 0 4 m36 2.1 0 w69 5.4 2.5 w27 0 4 m67 1.1 0
w73 5.4 22.5 m55 3.2 0 m38 2.1 2 w79 0 10 m35 14.9 4 m105 1.1 0 m43
19.6 5 m37 1.1 4 m127 1.1 0 m56 0 2.5 neg. 0 4 m40 14.9 2 neg. 3.6
12.5 m63 3.2 2 m101 2.1 12 neg. 3.2 8
TABLE 6 p30 USA France U.K. Brazil Spain Luxemb. Belgium w25 98.9
99.4 88.9 98.3 94.3 100.0 97.0 w29 2.5 0.6 0.0 1.7 0.0 0.0 0.0 w32
3.3 0.6 5.6 5.2 5.7 6.7 1.5 w36 2.5 0.0 0.0 3.4 0.0 0.0 1.0 m23 3.1
0.0 0.0 0.0 0.0 0.0 1.0 neg. 0.6 0.6 5.6 0.0 0.0 0.0 1.0 p46/48 USA
France U.K. Brazil Spain Luxemb. Belgium w47 94.2 80.5 83.3 89.7
97.1 73.3 82.9 w45 8.6 15.6 0.0 1.7 5.7 6.7 11.1 w72 4.2 0.0 16.7
0.0 2.9 13.3 5.0 m41 0.0 0.0 0.0 10.3 0.0 13.3 1.0 neg. 2.8 4.5 0.0
0.0 0.0 0.0 2.5 p50 USA France U.K. Brazil Spain Luxemb. Belgium
w31 96.4 97.4 100.0 96.6 100.0 100.0 96.5 w44 1.7 0.6 0.0 1.7 0.0
0.0 1.0 w52 10.0 4.5 0.0 1.7 2.9 6.7 9.0 m37 2.5 0.6 0.0 1.7 0.0
6.7 0.5 neg. 3.1 2.6 0.0 3.4 0.0 0.0 1.5 p54 USA France U.K. Brazil
Spain Luxemb. Belgium w34 96.9 82.5 97.2 87.9 100.0 53.3 89.4 w3
84.7 77.9 94.4 69.0 82.9 46.7 76.9 w14 3.3 5.8 0.0 3.4 11.4 0.0 6.5
w19 9.2 2.6 0.0 1.7 2.9 6.7 5.5 w22 2.8 10.4 0.0 0.0 5.7 0.0 2.5
w26 0.0 1.3 0.0 0.0 0.0 0.0 0.0 w27 0.0 1.9 0.0 0.0 0.0 0.0 0.5 m55
0.0 0.0 0.0 0.0 0.0 13.3 0.5 m35 1.1 0.0 2.8 6.9 0.0 46.7 3.0 m37
0.0 0.0 0.0 0.0 0.0 13.3 0.0 neg. 0.6 1.3 0.0 1.7 0.0 0.0 2.0
p82/84 USA France U.K. Brazil Spain Luxemb. Belgium w91 91.6 93.5
94.4 77.6 100.0 73.3 85.9 w60 6.4 2.6 0.0 1.7 2.9 13.3 5.5 w111 3.6
0.6 0.0 1.7 0.0 0.0 0.5 w89 7.0 1.9 0.0 3.4 0.0 0.0 3.0 w42 0.6 0.0
2.8 1.7 0.0 0.0 2.0 m36 0.3 0.0 0.0 0.0 0.0 0.0 0.0 m67 0.0 0.0 0.0
0.0 0.0 0.0 0.5 m38 0.0 0.0 0.0 0.0 0.0 6.7 0.0 m105 0.0 0.0 0.0
0.0 0.0 0.0 0.0 m127 0.0 0.0 0.0 0.0 0.0 0.0 0.0 m40 2.8 0.0 8.3
3.4 5.7 46.7 0.0 m63 0.3 0.0 0.0 1.7 2.9 13.3 0.5 m101 1.9 4.5 0.0
3.4 0.0 6.7 4.0 neg. 2.5 3.9 0.0 13.8 0.0 6.7 5.0 p90 USA France
U.K. Brazil Spain Belgium w27 51.1 45.5 34.3 47.7 52.8 25.7 w37
91.9 73.4 80.0 81.8 88.9 55.2 w39 0.0 0.0 0.0 0.0 0.0 2.9 w50 2.6
23.8 2.9 13.6 11.1 21.9 w52 8.4 11.2 5.7 6.8 13.9 4.8 w69 5.2 1.4
5.7 2.3 0.0 3.8 w73 6.1 9.1 0.0 0.0 8.3 6.7 w79 7.1 11.2 8.6 9.1
5.6 5.7 m43 1.9 0.0 11.4 0.0 0.0 8.6 m56 0.3 1.4 0.0 0.0 0.0 0.0
neg. 1.0 0.0 0.0 0.0 0.0 18.1
TABLE 7 Tm lengte Seq ID pc50w5 AGG GGG AAT TGG AGG TTT TA 20 511
26 27 28 29 30 31 32 33 34 35 ACA GGA GCA GAT GAT ACA GTA TTA GAA
GAA pc30w25 GCA GAT GAT ACA GT 40 14 31 pc30w29 A GCG GAT GAT ACA
36 13 35 pc30w32 GCA GAT GAC ACA GT 42 14 38 pc30w36 GCA GAC GAT
ACA GG 40 14 42 pc30m23 A GCA GAT AAT ACA GT 40 15 29 44 45 46 47
48 49 50 51 52 CCA AAA ATG ATA GGG GGA ATT GGA GGT pc48w37 ATG ATA
GGG GGA ATT 15 512 pc48w47 AAA ATG ATA GGG GGA 42 15 93 pc48w73 A
AGA ATG ATA GGG G 14 513 pc48w45 AAA ATG ATA GGA GGA ATT 42 18 91
pc48w72 A AAA ATA ATA GGG GGA 42 16 120 pc48m41 ATG ATA GTG GGA ATT
40 15 87 48 49 50 51 52 53 54 GGG GGA ATT GGA GGT TTT ATC pc50w31
GGA ATT GGA GGT TTT 42 15 151 pc50w44 GGA ATT GGG GGT TT 42 14 164
pc50w52 GA ATT GGA GGC TTG 14 172 pc50m37 GGG GGA GTT GGA 40 12 157
51 52 53 54 55 56 57 58 GGA GGT TTT ATC AAA GTA AGA CAG pc54w34 GA
GGT TTT ATC AAA GT 42 16 212 pc54w14 GGT TTT ATC AAG GTA A 42 16
189 pc54w19 A GGC TTT ATC AAA GTA 42 16 194 pc54w22 GA GGT TTT ATT
AAA GTA 42 17 197 pc54w26 A GGT TTC ATT AAG GTA 42 16 202 pc54w27
GGT TTT ATT AAG GTA A 40 16 204 pc54m35 GGT TTT GTC AAA GTA 40 15
213 pc54m37 GGT TTT GTC AGA GTA 42 15 215 pc54m55 A GGT TTT GCC AAA
GT 15 516 78 79 80 81 82 83 84 85 86 87 GGA CCT ACA CCT GTC AAC ATA
ATT GGA AGA pc82w91 ACA CCT GTC AAC ATA A 44 16 318 pc82w60 CA CCT
GTC AAT ATA ATG 42 17 287 pc82w111 A CCG GTC AAC ATA ATT 44 16 338
pc82w89 ACA CCT GTT AAC ATA AG 42 17 316 pc82m101 ACA CCT ATC AAC
ATA AT 17 517 pc82w42 CA CCT GTC AAC GTA 42 14 269 pc82m38 ACA CCT
TTC AAC ATA 40 15 265 pc82m105 ACG CCC TTC AAC ATA 44 15 332
pc82m127 CA CCT TTC AAC GTA ATG 44 17 354 pc82m40 ACA CCT GCC AAC
ATA 44 15 267 pc82m63 CA CCT GCC AAT ATA AG 42 16 290 pc82m36 ACA
CCT ACC AAC ATA 15 518 pc82m67 ACA CCT ACC AAC GT 14 519 86 87 88
89 90 91 92 93 94 GGA AGA AAT CTG TTG ACT CAG ATT GGT pc90w27 ATT
CTG TTG ACT CA 38 14 384 pc90w37 T CTG TTG ACT CAG AT 15 514
pc90w39 GA GTC AAC AGA GTT C 15 515 pc90w50 AAT ATG TTG ACT CAG 40
15 407 pc90w52 AAT TTG TTG ACT CAG 40 15 409 pc90w69 GA AAC CTG TTG
ACT 40 14 426 pc90w73 TG TTG ACA CAG CTT G 44 15 430 pc90w79 TG TTG
ACC CAG ATT G 44 15 436 pc90m138 GTC ATC AGA TTT CT 14 510 pc90m56
AAT ATG ATG ACC CAG 42 15 413
SEQUENCE LISTING <100> GENERAL INFORMATION: <160>
NUMBER OF SEQ ID NOS: 529 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 1 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 1 cagagccaac agccccacca g 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 2 <211> LENGTH: 27
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 2 atcaggatgg agttcataac ccatcca 27
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 3
<211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 3 cctcaratca
ctctttggca acg 23 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 4 <211> LENGTH: 25 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 4 taatcrggat aactytgaca tggtc 25 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 5 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 5 cctgtcaaca taattggaag 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 6
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 6 agtcaacaga
tttcttccaa t 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 7 <211> LENGTH: 18 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 7 agcagatgat acagtatt 18 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 8 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 8 gagcagatga tacagtatt 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 9
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 9 agcagatgat
acagtatta 19 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 10 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 10
ggagcagatg atacagtatt 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 11 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 11 ggagcagatg atacagtatt a 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 12 <211> LENGTH: 18
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 12 acaggagcag atgataca 18
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 13
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 13 caggagcaga
tgatacagt 19 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 14 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 14
aggagcagat gatacagtat g 21 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 15 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 15 ggagcagatg atacagtatg 20 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 16 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 16 acaggagcag atgatacagg 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 17
<211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 17 agcagataat
acagtatt 18 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 18 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 18
gagcagataa tacagtatt 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 19 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 19 agcagataat acagtatta 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 20 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 20 ggagcagata atacagtatt 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 21
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 21 ggagcagata
atacagtatt a 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 22 <211> LENGTH: 18 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 22 acaggagcag ataataca 18 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 23 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 23 caggagcaga taatacagt 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 24
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 24 aggagcagat
aatacagtat g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 25 <211> LENGTH: 20 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 25 ggagcagata atacagtatg 20 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 26 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 26 acaggagcag ataatacagg 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 27
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 27 agcagatgat
acagt 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 28 <211> LENGTH: 17 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 28
agcagatgat acagtag 17 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 29 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 29 agcagataat acagt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 30 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 30 agcagataat acagtag 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 31
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 31 gcagatgata cagt
14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 32
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 32 agcagatgat
acagg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 33 <211> LENGTH: 13 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 33
cagatgatac agt 13 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 34 <211> LENGTH: 14 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 34 gagcggatga taca 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 35 <211> LENGTH: 13
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 35 agcggatgat aca 13 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 36 <211>
LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 36 gcagataata cagta 15 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 37 <211>
LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 37 gcagataata cagt
14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 38
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 38 gcagatgaca cagt
14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 39
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 39 cagatgacac
agtag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 40 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 40
cagatgatac aatatt 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 41 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 41 gcagatgata caatatg 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 42 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 42 gcagacgata cagg 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 43 <211>
LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 43 gcagacgata cagt
14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 44
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 44 agatgataca
atatt 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 45 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 45
agatgataca atatta 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 46 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 46 gcagatgata caata 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 47 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 47 gtagggggaa ttggaggtgg 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 48
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 48 gtagggggaa
ttggaggttg 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 49 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 49
gtagggggaa ttggaggttt g 21 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 50 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 50 gtagggggaa ttggaggttt t 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 51 <211> LENGTH: 22
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 51 ggtaggggga attggaggtt tg 22
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 52
<211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 52 atggtagggg
gaattgga 18 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 53 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 53
atggtagggg gaattggag 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 54 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 54 aatggtaggg ggaattgga 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 55 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 55 aatggtaggg ggaattggag 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 56
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 56 aatggtaggg
ggaattggag gggg 24 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 57 <211> LENGTH: 18 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 57 ataatagggg gaattgga 18 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 58 <211> LENGTH: 18
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 58 atgatagggg gaattgga 18
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 59
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 59 aataataggg
ggaattgga 19 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 60 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 60
aatgataggg ggaattgga 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 61 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 61 atagggggaa ttggaggtgg 20 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 62 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 62 atagggggaa ttggaggttg 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 63
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 63 atagggggaa
ttggaggttt g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 64 <211> LENGTH: 21 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 64 atagggggaa ttggaggttt t 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 65 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 65 gtagtgggaa ttggaggtgg 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 66
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 66 gtagtgggaa
ttggaggttg 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 67 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 67
gtagtgggaa ttggaggttt g 21 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 68 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 68 gtagtgggaa ttggaggttt t 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 69 <211> LENGTH: 22
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 69 ggtagtggga attggaggtt tg 22
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 70
<211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 70 atggtagtgg
gaattgga 18 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 71 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 71
atggtagtgg gaattggag 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 72
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 72 aatggtagtg
ggaattgga 19 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 73 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 73
aatggtagtg ggaattggag 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 74 <211> LENGTH: 24 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 74 aatggtagtg ggaattggag gggg 24 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 75 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 75 atagtgggaa ttggaggtgg 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 76
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 76 atagtgggaa
ttggaggttg 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 77 <211> LENGTH: 18 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 77
atgatagtgg gaattgga 18 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 78 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 78 atgatagtgg gaattggag 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 79 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 79 aatgatagtg ggaattgga 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 80
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 80 gataggggga attg
14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 81
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 81 tgataggggg
aattg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 82 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 82
tgataggggg aattgg 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 83 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 83 atgatagggg gaatt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 84 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 84 gatagtggga attg 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 85 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 85 tgatagtggg
aattg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 86 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 86
tgatagtggg aattgg 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 87 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 87 atgatagtgg gaatt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 88 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 88 ataatagggg gaatt 15 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 89 <211>
LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 89 tgataggggg agtt
14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 90
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 90 gataggggga gttg
14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 91
<211> LENGTH: 18 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 91 aaaatgatag
gaggaatt 18 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 92 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 92
atgatagggg gaatt 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 93 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 93 aaaatgatag gggga 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 94 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 94 aaaaatgata ggggg 15 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 95 <211>
LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 95 aaatgatagg
gggaag 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 96 <211> LENGTH: 17 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 96
aaaataatag ggggaag 17 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 97 <211> LENGTH: 11 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 97 aaaataaaaa t 11 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 98 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 98 aaaatgatag tgggaag 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 99 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 99 aaattgatag gggg 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 100 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 100 aaaatgatag
tggga 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 101 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 101
aaattgatag gggga 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 102 <211> LENGTH: 12 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 102 caaaattgat ag 12 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 103 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 103 atggtagggg gaatt 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 104
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 104 aaatggtagg
ggga 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
105 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 105
aaaaatggta gggg 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 106 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 106 atgatagggg aaatt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 107 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 107 ataggggaaa ttgga 15
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 108 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 108 ataggggaaa ttggag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 109 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 109 atgatagggg ggatt 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 110
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 110 atagggggga
ttgg 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
111 <211> LENGTH: 13 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 111
aggggggatt gga 13 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 112 <211> LENGTH: 15 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 112 aaaataatag tggga 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 113 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 113 aaaaataata gtggga 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 114
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 114 caaaaataat
agtggg 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 115 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 115
aaattgatag tggga 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 116 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 116 aaaattgata gtggga 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 117 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 117 caaaattgat agtgg 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 118
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 118 aaaatgatag
gggg 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
119 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 119
aaaaatgata gggg 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 120 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 120 aaaaataata ggggga 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 121 <211> LENGTH: 18
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 121 gggggaattg gaggtttt 18
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 122
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 122 agggggaatt
ggaggtttt 19 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 123 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 123
tagggggaat tggaggtttt 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 124 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 124 agggggaatt ggaggtttta g 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 125 <211> LENGTH: 22
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 125 tagggggaat tggaggtttt ag 22
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 126
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 126 gtagggggaa
ttggaggttg g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 127 <211> LENGTH: 22 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 127 ggtaggggga attggaggtt gg 22 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 128 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 128 gtagggggaa ttggaggttt g 21
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 129
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 129 gtagggggaa
ttggaggttt t 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 130 <211> LENGTH: 22 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 130 tggtaggggg aattggaggt gg 22 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 131 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 131 ggggaattgg aggtttt 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 132
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 132 ggggaattgg
aggtttg 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 133 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 133
ggggaattgg aggttttag 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 134 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 134 ggggaattgg aggttg 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 135 <211> LENGTH: 18
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 135 gggaattgga ggttttat 18
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 136
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 136 ggggaattgg
aggtttt 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 137 <211> LENGTH: 18 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 137
gggggagttg gaggtttt 18 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 138 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 138 agggggagtt ggaggtttt 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 139 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 139 tagggggagt tggaggtttt 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 140
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 140 agggggagtt
ggaggtttta g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 141 <211> LENGTH: 22 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 141 tagggggagt tggaggtttt ag 22 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 142 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 142 gtagggggag ttggaggttg g 21
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 143
<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 143 ggtaggggga
gttggaggtt gg 22
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 144
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 144 gtagggggag
ttggaggttt g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 145 <211> LENGTH: 24 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 145 gtagggggag ttggaggttt tatc 24 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 146 <211> LENGTH: 22
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 146 tggtaggggg agttggaggt gg 22
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 147
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 147 ggggagttgg
aggtttg 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 148 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 148
ggggagttgg aggttttag 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 149 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 149 ggggagttgg aggttg 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 150 <211> LENGTH: 18
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 150 gggagttgga ggttttat 18
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 151
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 151 ggaattggag
gtttt 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 152 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 152
gggaattgga ggttgg 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 153 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 153 ggagttggag gtttt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 154 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 154 gggagttgga ggttgg 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 155
<211> LENGTH: 13 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 155 gggggagttg gag
13 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 156
<211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 156 ggggagttgg ag
12 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 157
<211> LENGTH: 12 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 157 gggggagttg ga
12 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 158
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 158 ggaattgggg
gtttg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 159 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 159
gaattggggg tttt 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 160 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 160 gaattggggg ttttag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 161 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 161 ggaattgggg gttg 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 162 <211>
LENGTH: 13 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 162 ggaattgggg gtg
13 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 163
<211> LENGTH: 13 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 163 gaattggggg ttg
13 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 164
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 164 ggaattgggg
gttt 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
165 <211> LENGTH: 13 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 165
gggggaattg cag 13 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 166 <211> LENGTH: 14 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 166 ggaattgcag gttg 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 167 <211> LENGTH: 13
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 167 ggaattgcag gtg 13 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 168 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 168 ggaattggag
ggttg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 169 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 169
gaattggagg gttg 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 170 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 170 gaattggagg gttt 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 171 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 171 ggaattggag gcttg 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 172
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 172 gaattggagg
cttg 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
173 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 173
gaattggagg cttt 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 174 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 174 ggagttggag gtttg 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 175 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 175 gagttggagg tttt 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 176 <211>
LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 176 ggttttatca
aagtaa 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 177 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 177
gttttatcaa agtaag 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 178 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 178 gttttatcaa agtaaga 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 179 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 179
ttttatcaaa gtaaga 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 180 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 180 ggttttatca aagta 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 181 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 181 gttttatcaa agta 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 182 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 182 ggttttgcca
aagta 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 183 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 183
gttttgccaa agtaa 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 184 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 184 gttttgccaa agtaag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 185 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 185 ttttgccaaa gtaaga 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 186
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 186 ggttttgcca
aagt 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
187 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 187
gttttgccaa agta 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 188 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 188 gttttatcaa ggtaaa 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 189 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 189 ggttttatca aggtaa 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 190
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 190 aggttttatc
aaggta 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 191 <211> LENGTH: 17 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 191
gttttatcaa agtcaga 17 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 192 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 192 tttatcaaag tcagac 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 193 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 193 aggctttatc aaagtaa 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 194
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 194 aggctttatc
aaagta 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 195 <211> LENGTH: 17 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 195
aggttttatt aaagtaa 17 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 196 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 196 ggttttatta aagtaag 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 197 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 197 gaggttttat taaagta 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 198
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 198 gaggttttat
taaagta 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 199 <211> LENGTH: 17 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 199
ggttttattg gttttat 17 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 200 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 200 ggtttcatta aggta 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 201 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 201 ggtttcatta aggtaa 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 202
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 202 aggtttcatt
aaggta 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 203 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 203
aggtttcatt aaggta 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 204 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 204 ggttttatta aggtaa 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 205 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 205 ggttttatta aggtaa 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 206
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 206 aggttttatt
aaggta 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 207 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 207
gaggttttat taaggt 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 208 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 208 ggttttatta aggtaag 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 209 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 209 ggttttatca aagtaa 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 210
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 210 aggttttatc
aaagtaa 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 211 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 211
aggttttatc aaagta 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 212 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 212 gaggttttat caaagt 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 213 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 213 ggttttgtca aagta 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 214
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 214 ggttttgtca
aagtaa 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 215 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus
<400> SEQUENCE: 215 ggttttgtca gagta 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 216 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 216 ggttttgtca gagtaa 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 217
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 217 gggtttatca
aagta 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 218 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 218
gggtttatca aagtaa 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 219 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 219 ggcttcatca aagt 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 220 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 220 gaggcttcat caaa 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 221 <211>
LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 221 ggttttgtca
aagt 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
222 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 222
gttttgtcag agta 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 223 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 223 ggttttgtca gagt 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 224 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 224 aggtttaatc aaagta 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 225
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 225 gaggtttaat
caaagt 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 226 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 226
ggttttacca aagta 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 227 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 227 ggttttacca aagt 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 228 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 228 cctacacctg tcaacataag 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 229
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 229 cctacacctg
tcaacataat g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 230 <211> LENGTH: 21 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 230 cctacacctg tcaacataat t 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 231 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 231 acctacacct gtcaacataa g 21
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 232
<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 232 acctacacct
gtcaacataa tg 22 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 233 <211> LENGTH: 19 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 233 acctacacct gtcaacata 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 234 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 234 gacctacacc tgtcaacata 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 235
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 235 cacctgtcaa
cataattgga 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 236 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 236
acctgtcaac ataattggaa 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 237 <211> LENGTH: 20 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 237 acacctgtca acataattgg 20 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 238 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 238 acctgtcaac ataattgga 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 239
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 239 cctacaccta
ccaacataag 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 240 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 240
cctacaccta ccaacataat g 21 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 241 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 241 cctacaccta ccaacataat t 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 242 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 242 acctacacct accaacataa g 21
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 243
<211> LENGTH: 22 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 243 acctacacct
accaacataa tg 22 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 244 <211> LENGTH: 19 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 244 acctacacct accaacata 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 245 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 245 gacctacacc taccaacata 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 246
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 246 cacctaccaa
cataattgga 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 247 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 247
acctaccaac ataattggaa 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 248 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 248 acacctacca acataattg 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 249 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 249 cctacacctt tcaacataat t 21
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 250
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 250 cctacacctg
ccaacataat t 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 251 <211> LENGTH: 21 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 251 cctacacctt ccaacataat t 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 252 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 252 acctttcaac ataattggaa 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 253
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 253 acctgccaac
ataattggaa 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 254 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 254
acctttcaac ataattggaa 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 255 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 255 acctaccaac ataatt 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 256 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 256 acctttcaac ataattgga 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 257
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 257 acctgccaac
ataattgga 19 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 258 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 258
accttccaac ataattgga 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 259 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 259 tacacctgtc aacat 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 260 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 260 tacacctgtc aacata 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 261
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 261 acacctgtca
acata 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 262 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 262
cacctgtcaa cata 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 263 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 263 acacctacca acata 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 264 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 264 cacctaccaa cata 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 265 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 265 acacctttca
acata 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 266 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 266
cacctttcaa cata 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 267 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 267 acacctgcca acata 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 268 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 268 cacctgccaa cata 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 269 <211>
LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 269 cacctgtcaa
cgta 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
270 <211> LENGTH: 13 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 270
cacctgtcaa cgt 13 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 271 <211> LENGTH: 15 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 271 cctacacctg tcaac 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 272 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 272 tacgcctgtc aacat 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 273
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 273 ctacgcctgt
caacag 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 274 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 274
acaccttcca acata 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 275 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 275 caccttccaa cata 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 276 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 276 acaccttcca acat 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 277 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 277 acacctatca
acata 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 278 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 278
cacctatcaa cataag 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 279 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 279 cacctatcaa cataatg 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 280 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 280 acctatcaac ataatg 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 281
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 281 cctgtcaaca
taatt 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 282 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 282
cctgttaaca taattg 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 283 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 283 acctgttaac ataatg 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 284 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 284 ccggtcaaca taatt 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 285
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 285 acgcctgtca
acat 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
286 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 286
cctgtcaata taatt 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 287 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 287 cacctgtcaa tataatg 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 288
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 288 acacctgtca
atataag 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 289 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 289
cctgccaata taatt 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 290 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 290 cacctgccaa tataag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 291 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 291 cctaccaacg taatt 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 292
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 292 cctaccaacg
taatg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 293 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 293
cacctaccaa cgta 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 294 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 294 acacctacca acgt 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 295 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 295 cctttcaacg taatt 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 296
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 296 cacctttcaa
cgtaag 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 297 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 297
acacctttca acgta 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 298 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 298 acctttcaac gtaatg 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 299 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 299 ctgtcaatat aattg 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 300
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated <400> SEQUENCE: 300 cctgtcaata taattg 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 301
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 301 acctgtcaat
ataatt 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 302 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 302
ctgtcaatat aattgg 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 303 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 303 cctacgcctg tcaa 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 304 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 304 ctacgcctgt caac 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 305 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 305 acctacgcct
gtcaa 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 306 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 306
acctacgcct gtca 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 307 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 307 tacaccggtc aaca 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 308 <211> LENGTH: 13
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 308 ctacaccggt caa 13 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 309 <211>
LENGTH: 13 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 309 cctacaccgg tca
13 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 310
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 310 cacctgtcaa
cataa 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 311 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 311
acctgtcaac ataat 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 312 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 312 ctacacctgt caaca 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 313 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 313 acacctgtca acat 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 314 <211>
LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 314 acctgttaac
ataattg 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 315 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 315
cacctgttaa cataag 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 316 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 316 acacctgtta acataag 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 317 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 317 tcacctgtca acata 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 318
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 318 acacctgtca
acataa 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 319 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 319
cacctgtcaa cataat 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 320 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 320 cctgtcaaca taatt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 321 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 321 acctgtcaac ataatt 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 322
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 322 cctgtcaaca
taattg 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 323
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 323 cctacacctg
tcaa 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
324 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 324
tgtcaacata attgg 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 325 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 325 tgtcaacata attgga 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 326 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 326 acacctttca acataa 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 327
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 327 tacacctttc
aacata 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 328 <211> LENGTH: 18 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 328
acacctatca acataatg 18 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 329 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 329 acacctatca acataag 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 330 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 330 cacctgccaa tataatg 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 331
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 331 acacctgcca
atataag 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 332 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 332
acgcccttca acata 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 333 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 333 cgcccttcaa cataag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 334 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 334 tacgcccttc aacat 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 335
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 335 ctacaccggt
caac 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
336 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 336
cctacaccgg tcaa 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 337 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 337 accggtcaac ataatg 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 338 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 338 accggtcaac ataatt 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 339
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 339 ctacaccagt
caac 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
340 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 340
ctacaccagt caaca 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 341 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 341 acaccagtca acata 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 342 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 342 acaccagtca acataag 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 343
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 343 tacgcctgtc
aacat 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 344 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 344
acgcctgtca acata 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 345 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 345 tacgcctgtc aaca 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 346 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 346 cctacacctt tcaac 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 347
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 347 ctacaccttt
caac 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
348 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 348
acctacacct ttcaa 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 349 <211> LENGTH: 18 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 349 acgcctgtca acataagg 18 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 350 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 350 tacgcctgtc aacata 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 351
<211> LENGTH: 17 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 351 cgcctgtcaa
cataagg 17 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 352 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 352
tacacctttc aacgta 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 353 <211> LENGTH: 18 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 353 acacctttca acgtaagg 18 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 354 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 354 cacctttcaa cgtaatg 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 355
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 355 acctttcaac
gtaatt 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 356 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 356
caacgtaatt ggaaga 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 357 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 357 caacgtaatt ggaag 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 358 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 358 aaatctgttg actcag 16
<200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 359 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 359 gaaatctgtt gactcag 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 360 <211> LENGTH: 20
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 360 gaaatctgtt gactcagagg 20
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 361
<211> LENGTH: 19 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 361 aaatctgttg
actcagagg 19 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 362 <211> LENGTH: 21 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 362
agaaatctgt tgactcagag g 21 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 363 <211> LENGTH: 21 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 363 agaaatctgt tgactcagat g 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 364 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 364 agaaatctgt tgactcagat t 21
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 365
<211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 365 agaaatctgt
tgactcagat tgg 23 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 366 <211> LENGTH: 23 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 366 gaagaaatct gttgactcag agg 23 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 367 <211> LENGTH: 22
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 367 aagaaatctg ttgactcaga tg 22
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 368
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 368 agaaatctga
tgactcagat g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 369 <211> LENGTH: 21 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 369 agaaatctga tgactcagat t 21 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 370 <211> LENGTH: 22
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 370 aagaaatctg atgactcaga gg 22
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 371
<211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 371 gaagaaatct
gatgactcag agg 23 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 372 <211> LENGTH: 22 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 372 aagaaatctg atgactcaga tg 22 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 373 <211> LENGTH: 23
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 373 gaagaaatct gatgactcag att 23
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 374
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 374 ggaagaaatc
tgatgactca g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 375 <211> LENGTH: 19 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 375 aagaaatctg atgactcag 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 376 <211> LENGTH: 21
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 376 aaatctgatg actcagattg g 21
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 377
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 377 aaatctgatg
actcagattg 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 378 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 378
aaatctgatg actcagcttg 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 379 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 379 aaatctgatg actcagctt 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 380 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 380 aatctgatga ctcagcttg 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 381
<211> LENGTH: 20 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 381 aaatctgttg
actcagcttg 20 <200> SEQUENCE CHARACTERISTICS: <210> SEQ
ID NO 382 <211> LENGTH: 19 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 382
aaatctgttg actcagctt 19 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 383 <211> LENGTH: 19 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 383 aatctgttga ctcagcttg 19 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 384 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 384 aatctgttga ctca 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 385 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 385 aatctgttga
ctcag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 386 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 386
aaatctgttg actca 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 387 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 387 aaatctgttg actcag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 388 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 388 aatctgatga ctca 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 389 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 389 aatctgatga
ctcag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 390 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 390
aaatctgatg actca 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 391 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 391 aaatctgatg actcag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 392 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 392 gaaatctgtt gactc 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 393
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 393 gaactctgtt
gactc 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 394 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 394
tctgttgact cagatg 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 395
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 395 gaaatctgtt
gactc 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 396 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 396
gaactctgtt gactc 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 397 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 397 aaatctgttg actca 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 398 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 398 aatctgttga ctcag 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 399
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 399 aatctgatga
ctcag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 400 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 400
aaatctgatg actca 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 401 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 401 atctgttgac tcagag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 402 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 402 ctgttgactc agatt 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 403
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 403 agaaatctgt
tgact 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 404 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 404
atctgatgac tcagag 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 405 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 405 ctgatgactc agatt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 406 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 406 agaaatctga tgactca 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 407
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 407 aatatgttga
ctcag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 408 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 408
gaaatatgtt gactca 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 409 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 409 aatttgttga ctcag 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 410 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 410 gaaatttgtt gactca 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 411
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 411 aatatgttga
cccag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 412 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 412
aaatatgttg accca 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 413 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 413 aatatgatga cccag 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 414 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 414 acagatgatg accca 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 415
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 415 aacatgttga
ctcag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 416 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 416
aaacatgttg actcag 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 417 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 417 tgttgactca gctt 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 418 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 418 ctgttgactc agctg 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 419
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 419 ctatgactca
gctt 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
420 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 420
ctgatgactc agcg 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 421 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 421 tgactacaca gctt 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 422 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 422 ctgttgacac agcg 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 423 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 423 aatctgttga
cacag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 424 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 424
aacctgttga ctca 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 425 <211> LENGTH: 14 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 425 aaacctgttg actc 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 426 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 426 gaaacctgtt gact 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 427 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 427 tgttgactca
gattg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 428 <211> LENGTH: 17 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 428
tgttgactca gattggg 17 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 429 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 429 gttgactcag attggg 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 430 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 430
tgttgacaca gcttg 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 431 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 431 ctgttgacac agctt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 432 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 432 gttgacacag cttggg 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 433
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 433 tgttgactca
gcttg 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 434 <211> LENGTH: 13 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 434
gttgactcag atg 13 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 435 <211> LENGTH: 14 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 435 gttgactcag cttg 14 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 436 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 436 tgttgaccca gattg 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 437
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 437 gttgacccag
attg 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
438 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 438
gttgacccag attggg 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 439 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 439 tgatgactca gattg 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 440 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 440 tgatgactca gattggg 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 441
<211> LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 441 gatgactcag
attggg 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 442 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 442
gatgactcag attggt 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 443 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 443 ctgatgactc agctt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 444 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 444 tgatgactca gcttg 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 445
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 445 aaatctgttg
actca 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 446 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 446
aaatctgttg actca 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 447 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 447 aaatctgttg actca 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 448 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 448 aatctgatga ctcag 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 449
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 449 aaatctgatg
actca 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 450 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 450
gaaatctgat gactc 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 451 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 451 ctgatgactc agatg 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 452 <211> LENGTH: 12
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 452 agaaatatga tg 12 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 453 <211>
LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 453 aagaaatatg
atgact 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 454 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 454
aagaaatctg atgact 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 455 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 455 aagaaatata atgact 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 456 <211> LENGTH: 16
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 456 aaatataatg actcag 16
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 457
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 457 aatatgatga
cccag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 458 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 458
aacctgatga ctcag 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 459 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 459 agaaatttga tgactc 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 460 <211> LENGTH: 19
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 460 aaatttgatg actatgact 19
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 461
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 461 acctgatgac
tcag 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
462 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 462
aatctgatga ctcaga 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 463 <211> LENGTH: 17 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 463 atctgatgac tcagatg 17 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 464 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 464 atctgatgac tcag 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 465 <211>
LENGTH: 16 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 465 ctgatgactc
agattg 16 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 466 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus
<400> SEQUENCE: 466 agaaatctga tgactc 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 467 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 467 agaaatctga tgact 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 468
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 468 gaagaaatct
gatga 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 469 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 469
ggaagaaatc tgatga 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 470 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 470 gaagaaatct gatgac 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 471 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 471 agaaatctga tgac 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 472 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 472 aatctgttaa
ctcag 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 473 <211> LENGTH: 16 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 473
tctgttaact cagatt 16 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 474 <211> LENGTH: 16 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 474 atctgttaac tcagag 16 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 475 <211> LENGTH: 15
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 475 agaaatttgt tgact 15
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 476
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 476 gaaatttgtt
gactc 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 477 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 477
aatttgttga ctcag 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 478 <211> LENGTH: 24 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 478 ggaggtttta tcaaagtcag acaa 24 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 479 <211> LENGTH: 24
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 479 ggaggtttca ttaaggtaaa acag 24
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 480
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 480 ggaggtttta
ttaaggtaag acag 24 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 481 <211> LENGTH: 24 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 481 ggaggtttta ttaaagtaag acaa 24 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 482 <211> LENGTH: 24
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 482 ggaggcttta tcaaagtaag acaa 24
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 483
<211> LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 483 ggaggtttta
tcaaagtcag acaa 24 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 484 <211> LENGTH: 26 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 484 ggacctacac cggtcaacat aattgg 26 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 485 <211> LENGTH: 26
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 485 ggacctacac ctgccaatat aattgg
26 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 486
<211> LENGTH: 26 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 486 ggacctacgc
ccttcaacat aattgg 26 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 487 <211> LENGTH: 26 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 487 ggaccgacac ctgtcaccat aattgg 26 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 488 <211> LENGTH: 26
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 488 ggacctatac ctgtcaacat aattgg
26 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 489
<211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 489 aaaaaatctg
atgactcaga ttggc 25 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 490 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 490 aagaactctg ttgactcagc ttgga 25 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 491 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 491 aagaaatatg atgacccagc ttggc 25
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 492
<211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 492 aagaaatata
atgactcagc ttgga 25 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 493 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 493 aagaaatctg ctgactcaga ttggg 25 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 494 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 494 aagaaatctg ttgacacagc ttggc 25
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 495
<211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 495 aagaaatatg
ttgactcagc ttggt 25 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 496 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 496 aagaaatttg ttgactcaga ttggg 25 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 497 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 497 aagaaatatg ttgactcagc ttggt 25
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 498
<211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 498 aagaaatatg
ttgactcagc ttgga 25 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 499 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 499 aagaaatctg ttgactcagc ttgga 25 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 500 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 500 aagaaacctg ttgactcaac ttggt 25
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 501
<211> LENGTH: 21 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 501 cagagccaac
agccccacca g 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 502 <211> LENGTH: 26 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 502 ttttcttctg tcaatggcca ttgttt 26 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 503 <211> LENGTH: 23
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 503 cctcaaatca ctctttggca acg 23
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 504
<211> LENGTH: 23 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 504 cctcagatca
ctctttggca acg 23 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 505 <211> LENGTH: 20 <212> TYPE: DNA
<213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 505 cctgtcaaca taattgcaag 20 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 506 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 506 ctggtacagt ttcaataggg ctaat 25
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 507
<211> LENGTH: 25 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 507 ctggtacagt
ttcaatagga ctaat 25 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 508 <211> LENGTH: 25 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 508 ctggtacagt ctcaatagga ctaat 25 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 509 <211> LENGTH: 25
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 509 ctggtacagt ctcaataggg ctaat 25
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 510
<211> LENGTH: 14 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 510 gtcatcagat
ttct 14 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO
511 <211> LENGTH: 20 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 511
agggggaatt ggaggtttta 20 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 512 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 512 atgatagggg gaatt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 513 <211> LENGTH: 14
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 513 aagaatgata gggg 14 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 514 <211>
LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 514 tctgttgact
cagat 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 515 <211> LENGTH: 15 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 515
gagtcaacag agttc 15 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 516 <211> LENGTH: 15 <212> TYPE:
DNA <213> ORGANISM: Aids-associated retrovirus <400>
SEQUENCE: 516 aggttttgcc aaagt 15 <200> SEQUENCE
CHARACTERISTICS: <210> SEQ ID NO 517 <211> LENGTH: 17
<212> TYPE: DNA <213> ORGANISM: Aids-associated
retrovirus <400> SEQUENCE: 517 acacctatca acataat 17
<200> SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 518
<211> LENGTH: 15 <212> TYPE: DNA <213> ORGANISM:
Aids-associated retrovirus <400> SEQUENCE: 518 acacctacca
acata 15 <200> SEQUENCE CHARACTERISTICS: <210> SEQ ID
NO 519 <211> LENGTH: 14 <212> TYPE: DNA <213>
ORGANISM: Aids-associated retrovirus <400> SEQUENCE: 519
acacctacca acgt 14 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 520 <211> LENGTH: 30 <212> TYPE:
DNA <213> ORGANISM: AIDS-associated retrovirus <400>
SEQUENCE: 520 acaggagcag atgatacagt attagaagaa 30 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 521 <211>
LENGTH: 33 <212> TYPE: DNA <213> ORGANISM:
AIDS-associated retrovirus <400> SEQUENCE: 521 ccaaaaatga
tagggggaat tggaggtttt atc 33 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 522 <211> LENGTH: 30 <212> TYPE:
DNA <213> ORGANISM: AIDS-associated retrovirus <400>
SEQUENCE: 522 aaaatgatag ggggaattgg aggttttatc 30 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 523 <211>
LENGTH: 24 <212> TYPE: DNA <213> ORGANISM:
AIDS-associated retrovirus <400> SEQUENCE: 523 ggaggtttta
tcaaagtaag acag 24 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 524 <211> LENGTH: 30 <212> TYPE:
DNA <213> ORGANISM: AIDS-associated retrovirus <400>
SEQUENCE: 524 ggacctacac ctgtcaacat aaatggaaga 30 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 525 <211>
LENGTH: 27 <212> TYPE: DNA <213> ORGANISM:
AIDS-associated retrovirus <400> SEQUENCE: 525 ggaagaaatc
tgttgactca gattggt 27 <200> SEQUENCE CHARACTERISTICS:
<210> SEQ ID NO 526 <211> LENGTH: 23 <212> TYPE:
DNA <213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide
<400> SEQUENCE: 526 cctcaratca ctctttggga acg 23 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 527 <211>
LENGTH: 21 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Synthetic oligonucleotide <400> SEQUENCE: 527 taaccttctt
tagacaactg a 21 <200> SEQUENCE CHARACTERISTICS: <210>
SEQ ID NO 528 <211> LENGTH: 20 <212> TYPE: DNA
<213> ORGANISM: Artificial Sequence <220> FEATURE:
<223> OTHER INFORMATION: Synthetic oligonucleotide
<400> SEQUENCE: 528 cctgtcaaca taattggaag 20 <200>
SEQUENCE CHARACTERISTICS: <210> SEQ ID NO 529 <211>
LENGTH: 25 <212> TYPE: DNA <213> ORGANISM: Artificial
Sequence <220> FEATURE: <223> OTHER INFORMATION:
Synthetic oligonucleotide <400> SEQUENCE: 529 taatcrggat
aactytgaca tggtc 25
* * * * *